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Abstract——The solute carrier (SLC) superfamily
comprises more than 400 transport proteins mediating
the influx and efflux of substances such as ions, nucleo-
tides, and sugars across biological membranes. Over 80
SLC transporters have been linked to human diseases,
including obesity and type 2 diabetes (T2D). This
observation highlights the importance of SLCs for
human (patho)physiology. Yet, only a small number of
SLC proteins are validated drug targets. The most
recent drug class approved for the treatment of T2D
targets sodium–glucose cotransporter 2, product of the
SLC5A2 gene. There is great interest in identifying
other SLC transporters as potential targets for the
treatment of metabolic diseases. Finding better treat-
ments will prove essential in future years, given the
enormous personal and socioeconomic burden posed by
more than 500 million patients with T2D by 2040 world-
wide. In this review,we summarize the evidence for SLC
transporters as target structures in metabolic disease.
To this end, we identified SLC13A5/sodium-coupled
citrate transporter, and recent proof-of-concept
studies confirm its therapeutic potential in T2D
and nonalcoholic fatty liver disease. Further SLC trans-
porters were linked in multiple genome-wide association
studies to T2D or related metabolic disorders. In
addition to presenting better-characterized potential
therapeutic targets, we discuss the likely unnoticed link
between other SLC transporters and metabolic disease.
Recognition of their potential may promote research on
these proteins for future medical management of human
metabolic diseases such as obesity, fatty liver disease,
and T2D.
Significance Statement——Given the fact that the
prevalence of human metabolic diseases such as obe-
sity and type 2 diabetes has dramatically risen, phar-
macological intervention will be a key future approach
to managing their burden and reducing mortality. In
this review, we present the evidence for solute carrier
(SLC) genes associated with human metabolic diseases
and discuss the potential of SLC transporters as ther-
apeutic target structures.
I. Introduction
Metabolic processes convert nutrients to energy and
build up proteins, lipids, carbohydrates, and nucleic
acids, also implicating the chemical reactions that
facilitate these processes, such as the intra- and in-
tercellular transport of substances. Thus, metabolism
maintains cell structure and function and keeps the cell
and the whole organism alive. Dysregulation of these
pathways, whether through genetic and/or environmen-
tal factors, can drive metabolic diseases. The most
common metabolic disease is type 2 diabetes (T2D),
posing a pandemic health threat with 425 million
affected people worldwide. T2D damages the heart,
brain, blood vessels, eyes, kidney, and nerves, thereby
increasing the risk of premature death. Obesity is the
major risk factor for T2D and is associated with ectopic
fat accumulation in the liver [nonalcoholic fatty liver
disease (NAFLD)] and insulin resistance, a pathological
state characterized by the inability of insulin to prop-
erly coordinate glucose homeostasis. Overnutrition and
an unhealthy diet coupled with a sedentary lifestyle
dramatically increase the prevalence of obesity, fatty
liver, insulin resistance, and T2D, particularly in
genetically predisposed individuals. Despite modern
therapies, including lifestyle intervention, medication,
and surgery, patients with T2D exhibit two to three
times increased mortality (Engelmann et al., 2016).
Approximately 1.6 million people die each year from
diabetes sequelae, particularly cardiovascular disease
(www.who.int). Antihyperglycemic treatments reduce
microvascular complications. Metformin is generally
recommended as first-line therapy in patients with
T2D. Evidence from recent cardiovascular outcome
trials led to the recommendation by the American
Diabetes Association and the European Association
for the Study of Diabetes to prescribe sodium–glucose
cotransporter (SGLT)2 inhibitors or glucagon-like pep-
tide 1 receptor agonists as preferred second medication
in patients with T2D and established cardiovascular
disease (Davies et al., 2018). Thus, novel drug targets
may beget therapies that further reduce diabetes
complications, which are urgently needed in the face
of the T2D pandemic.
Genome-wide association studies (GWAS) or Mende-
lian randomization (MR) studies can be used to iden-
tify new therapeutic targets in human beings. These
approaches reveal single-nucleotide polymorphisms
(SNPs) as risk factors associated with human diseases.
Up to now, GWAS and other sequencing studies have
linked more than 140 gene loci to T2D. Of these, 15 loci
cover genes encoding putative or known membrane
transport proteins (Morris, 2018). Membrane trans-
porters are crucial for cellular homeostasis and serve
as cellular gatekeepers by controlling the trafficking
of molecules such as sugars, amino acids, fatty acids,
nucleotides, inorganic ions, and drugs (Hediger et al.,
2004). Through selective transport across biological mem-
branes, cells are able to adapt to metabolic challenges,
which is critical for the maintenance of physiological
processes. Indeed, about 2000 human genes—equivalent
to about 10% of all human genes—are predicted to be
related to membrane transport proteins (Hediger
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et al., 2004). Functional gene variants of transport
proteins are involved in human diseases, and about
10% of established T2D loci are related to membrane
transporters.
II. Solute Carrier Membrane Transport Proteins
Solute carrier (SLC) proteins are a group of trans-
membrane transporters that mediate solute influx
and efflux across plasma and intracellular membranes
(Hediger et al., 2004). The SLC nomenclature system
was introduced in the 1990s byMatthias A. Hediger and
Phyllis McAlpine, the first chair of the Human Genome
Organization Gene Nomenclature Committee (HGNC).
An overview of all currently known SLC genes is
provided in the SLC tables (slc.bioparadigms.org) and
the HGNC database (www.genenames.org/cgi-bin/
genefamilies/set/752). Both overlap; however, some
entries differ (Perland and Fredriksson, 2017). The
publication of the first mini-review on SLCs pre-
sented 298 genes grouped in 43 SLC families
(Hediger et al., 2004). At present, it comprises over
60 families with more than 400 genes, and new
transporter genes continue to be discovered and
added to the SLC superfamily. The ongoing SLC
research has yielded hitherto unknown contributions
to health and disease, making them increasingly
important as drug targets.
A. Definitions: Solute Carrier Superfamily and Other
Membrane Transporters
Membrane transporter classification into SLCs and
other transport proteins—so-called non-SLCs—was in-
troduced in 2004. The classification within the SLC
transporter superfamily is based exclusively on biolog-
ical function and not on sequence homology. Members of
the same SLC transporter family that share similar
substrates show an at least 20% protein sequence
identity (Hediger et al., 2004).
The two main membrane transport protein classes
are channels and carriers. Carriers feature substrate-
binding sites that undergo conformational changes to
move substrates across membranes and transport-
defined substrate quantities per translocation cycle.
Conversely, substrates passively flow through chan-
nels. Carriers are classified into active and passive
transporters (Hediger, 1994). SLCs mediate passive
and secondary active substrate transport. Passive or
facilitated transport (uniport) does not require en-
ergy input because solutes are transported along an
electrochemical gradient. Substance transport against
electrochemical gradients requires energy-providing
mechanisms and is mediated by active transporters
that are divided into primary and secondary active
transporters. Secondary active transporters facilitate
substance transfer against an electrochemical gradient.
The process is coupled with ion movements down an
electrochemical gradient, thus providing energy for
active substance transport. When substance and driving
ion are transferred in the same direction, the trans-
porter is termed a cotransporter (symporter), whereas
exchangers (antiporter) translocate molecules in oppo-
site directions.
The SLC superfamily includes passive transporters
as well as secondary active transporters, whereas non-
SLC transporters include channels and primary active
transporters (Hediger et al., 2004). In contrast to
carriers, channels mediate ion or solute flow at high
rates controlled by gating mechanisms, that is, pore
opening and closing. Primary active transporters are
ATP dependent and include the family of ATP-binding
cassette transporter and ATPases (ion pumps). Both
transporters transfer their substrates out of cells or into
cellular organelles and bind or hydrolyze ATP to trans-
port substances such as ions, lipids, carbohydrates,
xenobiotics, and drugs (ATP-binding cassette trans-
porter), or transport ions coupled to ATP hydrolysis
(ATPases).
B. Solute Carrier–Related Human Diseases
The important role of SLC transporters in metabo-
lism is reflected by their expression profile, with high
levels in metabolically active organs such as the liver,
kidney, brain, and intestine, and by links with human
diseases. SLC transporter defects contribute to Mende-
lian and complex multifactorial diseases. SLC-related
diseases range from neurological disorders associated
with neurotransmitter transporter dysfunction of
the SLC1 or SLC6 family such as amyotrophic lateral
sclerosis, Parkinson disease, Alzheimer’s disease,
epilepsy, schizophrenia, or autism (Pramod et al.,
2013; Grewer et al., 2014), to less common diseases
such as Bartter and Gitelman syndrome, nephro-
pathic conditions caused by mutations in SLC12
genes encoding renal cation-coupled chloride trans-
porters (Hebert et al., 2004). More general overviews
on SLC transporters in human diseases and their
potential as drug targets have been published re-
cently (Rask-Andersen et al., 2013; Lin et al., 2015;
Zhang et al., 2019). In contrast, our review focuses on
SLC transporters that are linked to metabolic dis-
eases and therefore presents promising novel drug
targets with which to treat T2D and associated
metabolic disorders.
C. Solute Carriers as Drug Targets
Transport proteins are, besides receptors and
enzymes, the third most common class of pharmacolog-
ical targets, with 67 target genes corresponding to
15% of all human drug targets (Rask-Andersen et al.,
2011). Currently, over 900 transporter-encoding genes
are listed in the HGNC dataset. With over 40% of these
genes, the SLC superfamily encodes the largest group of
membrane transporters in humans (Hediger et al., 2013).
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Despite their important physiological functions and
known links to human diseases—over 80 SLC trans-
porters have been implicated in genetic disorders (Lin
et al., 2015)—only a small number of approved drugs
target SLC transporters. Compared with other classes
of human drug targets, the SLC superfamily appears
understudied in relation to drug target discovery,
potentially for a number of reasons: SLCs have only
recently been characterized, and the area is still
evolving. A lack of structural characterization of hu-
man SLC membrane proteins impedes drug design.
Moreover, SLC transporters fulfill essential functions
and are broadly expressed and redundant in their
substrate specificity, making a specific pharmacological
intervention even more challenging (Rask-Andersen
et al., 2013).
Over 30 SLC proteins have recently been presented
as current, prospective, or potential drug targets (Rask-
Andersen et al., 2013; Lin et al., 2015; Zhang et al.,
2019). More stringent analyses revealed 12 drug clas-
ses, including those proposed in the recent reviews, that
are approved by the Food and Drug Administration
(FDA) and whose primary mode of action is mediated
selectively through one SLC or nonselectively through
at least two SLCs (César-Razquin et al., 2015). The drug
classes target the SLC5, SLC6, SLC12, SLC18, SLC22,
SLC25, and SLC29 families. Six additional drugs
targeting SLC5, SLC6, SLC9, SLC10, SLC22, and
SLC40 family members are being tested in phase II
clinical trials or beyond (César-Razquin et al., 2015).
Importantly, the SLC family is expected to be generally
druggable using small-molecule compounds, and about
75% of SLCs are predicted to bind small organic
molecules (César-Razquin et al., 2015). In general, most
drugs use known binding sites; it is clear that the higher
the similarity between compound and endogenous
ligands, the higher the probability of affecting the
biological action of the transporter (Fauman et al.,
2011). Indeed, for the majority of well-studied SLCs,
small-molecule inhibitors have already been reported
(César-Razquin et al., 2015). Further elucidation of
physiological functions and three-dimensional SLC
structures will provide new opportunities for drug
development. However, membrane proteins are diffi-
cult to crystallize. It is hoped that new strategies for
membrane protein crystallization and computational
analyses methods will reveal high-resolution human
SLC structures that can guide site-directed mutagene-
sis to uncover substrate-binding sites and functionally
important domains. Ultimately, structure-based drug
design may foster the translation of potential SLC
targets into clinical practice.
1. Solute Carrier 5A1/Sodium–Glucose Cotransporter
1 and Solute Carrier 5A2/Sodium–Glucose Cotrans-
porter 2. The successful clinical introduction of SGLT2
inhibitors is a prime example for the emerging potential
of SLC transporters as drug targets. SGLT1 and SGLT2,
encoded by theSLC5A1 andSLC5A2 genes, respectively,
are members of the SGLT family. Both transporters
are crucial for glucose reabsorption in proximal renal
tubules. Loss-of-function mutations in SLC5A1 are
linked to glucose–galactose malabsorption in humans,
a condition characterized by severe watery diarrhea
in newborns (Lindquist and Meeuwisse, 1962; Turk
et al., 1991; Wright et al., 2001). Patients with glucose–
galactose malabsorption are lifelong glucose and galac-
tose intolerant, but can lead a normal life on a sugar-free
diet. The finding that SLC5A2mutations cause familial
glucosuria implicated the transporter in glucose ho-
meostasis (Santer et al., 2000, 2003; van den Heuvel
et al., 2002). Affected individuals exhibit urinary
glucose excretion up to .100 g/day in the face of
euglycemia without renal tubular dysfunction. The
condition is considered relatively benign because it
rarely leads to hypoglycemia.
The discovery that phlorizin, a naturally occurring
compound isolated from apple tree bark, lowers blood
glucose levels through SGLT inhibition was key to the
development of the class of SGLT inhibitors. Phlorizin
was shown to inhibit human renal glucose reabsorption
in the 1930s (Chasis et al., 1933). Studies in the 1980s
showed that the compound restores normal glucose
levels in partially pancreatectomized rats and corrected
the insulin secretion defect induced by hyperglycemia
(Rossetti et al., 1987; Kahn et al., 1991). Eventually,
the beneficial response was attributed to dual SGLT1
and SGLT2 inhibition (Toggenburger et al., 1982;
Ehrenkranz et al., 2005). Glucose reabsorption from
the tubular lumen into the cell through SGLTs is driven
by an ATPase-generated sodium concentration gradi-
ent. After absorption by SGLTs, glucose exits the cell
through SLC family 2–facilitated glucose transport
member 2, entering the bloodstream and contributing to
glycemic variance. SGLT2 reclaims more than
90% of filtered glucose (Vallon et al., 2011). Glucose,
which is not reabsorbed via SGLTs, is excreted in urine,
which is promoted by SGLT inhibition and counteracts
hyperglycemia.
Gastrointestinal side effects such as nausea and
vomiting, and pharmacokinetic issues limiting oral
dosing halted the clinical development of phlorizin as
an oral antidiabetic agent (Ehrenkranz et al., 2005).
Meanwhile, other SGLT-targeting compounds have
been generated and approved for the treatment of
T2D. Currently, four selective SGLT2 inhibitors are
FDA-approved for mono- and combination therapy:
canagliflozin, dapagliflozin, empagliflozin, and ertugli-
flozin (Fioretto et al., 2015; Scheen, 2015; Shubrook
et al., 2015; Triplitt and Cornell, 2015; Derosa and
Maffioli, 2018). Others are in the pipeline and may
be approved in the near future, such as sotagliflozin
(McCrimmon and Henry, 2018). Of the four FDA-
approved drugs, empagliflozin has the highest selec-
tivity for SGLT2 compared with SGLT1, whereas
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canagliflozin is the least selective (Hsia et al., 2017). In
phase II and phase III clinical trials, SGTL2 inhibition
reduced glycated hemoglobin, HbA1c, in patients with
diabetes by 0.5% to 1%. It also produces modest weight
loss, reduces arterial blood pressure, induces glucosuria
with osmotic diuresis and natriuresis, and reduces intra-
hepatic lipid content (Fioretto et al., 2015; Scheen, 2015;
Shubrook et al., 2015; Triplitt and Cornell, 2015; Derosa
and Maffioli, 2018; Kahl et al., 2019). In large-scale
international, multicenter cardiovascular safety trials,
including the EMPA-REG OUTCOME, the CANVAS
Program, and DECLARE-TIMI 58, SGLT2 inhibition
reduced cardiovascular endpoints (Zinman et al., 2015;
Neal et al., 2017; Wiviott et al., 2019). In a meta-
analysis of the three trials, SGLT2 inhibition reduced
major adverse cardiovascular events, with benefits
restricted to patients with atherosclerotic cardiovascu-
lar disease (Zelniker et al., 2019). Overall, proven
benefits in cardiovascular outcome trials with a rela-
tively benign safety profile support the use of the
SGLT2 inhibitors in the treatment of patients with
T2D and cardiovascular disease, heart failure, and
diabetic kidney disease (Davies et al., 2018). More
recent trials also establish the role of SGLT2 inhibitors
in the treatment of type 1 diabetes (Mathieu et al., 2018;
Rosenstock et al., 2018).
III. Links to Human Metabolic Disease and
Potential Targets
From a pharmacological perspective, membrane
transporters have the potential to fulfill two important
functions, as follows: they can directly serve as drug
targets, or deliver drugs modulating other cellular
targets (Hediger et al., 2004). In this review, we focus
on drug targets, which in functional and/or genetic
studies have been previously linked to humanmetabolic
diseases. Themetabolic phenotypes of interest comprise
obesity, NAFLD, insulin resistance, and T2D. Further-
more, our main goal was to characterize physiology and
pathophysiology associated with SLCs rather than de-
tailed transporter structure and transport mechanism.
Importantly, we evaluated the therapeutic potential
of selected family members on the basis of animal and
human investigations. For some SLCs, the link to
human metabolic disease and the rationale of modulat-
ing its activity for therapeutic purposes are strong.
For example, GWAS of larger populations, well-
characterized inherited disorders, and/or valid mouse
models may have yielded promising data, supporting
the role of the SLC in the development, prevention, or
cure of metabolic disease. Such investigational targets
are presented in this section. Table 1 displays an over-
view of SLCs that we consider conclusive candidates for
clinical development as well as SLCs targeted by already
approved drugs such as SGLT2. For these transporters,
Figs. 1 and 2 display their cellular localization and tissue
expression. Moreover, we present other selected mem-
bers that do not currently have a fully convincing data
set because existing association studies are lacking or
only performed in small populations, disease patterns
are not closely linked or are less well studied in terms of
metabolic disease, or are only supported by mouse data.
These candidates are promising for future research, and
are presented in Emerging Potential of Other Solute
Carrier Target Structures and summarized in Table 2.
A. Solute Carrier 13: The Sodium–Sulfate/
Carboxylate Cotransporter Family
The tricarboxylic acid (TCA) cycle is essential for
energy synthesis under aerobic conditions. It provides
substrates and thereby regulates multiple metabolic
reactions, including glucose and lipid metabolism. TCA
cycle intermediates such as citrate, succinate, and
a-ketoglutarate are transported across the plasma
membrane into the cell by sodium (Na1)-coupled anion
transporters of the SLC13 family, regulating levels of
these metabolites in plasma, urine, and tissue. These
transporters are ubiquitously expressed, but primar-
ily in the liver, kidney, small intestine, and brain
(Pajor, 2014). The human SLC13 family consists of five
genes—SLC13A1, SLC13A2, SLC13A3, SLC13A4,
and SLC13A5—and is divided into two functionally
unrelated groups, as follows: the sodium-coupled di-
and tricarboxylate transporters (NaDC), also termed
sodium–carboxylate transporters (NaC), including
NaDC1/NaC1 (SLC13A2), NaDC3/NaC3 (SLC13A3),
and NaC2, also sodium-coupled citrate transporter
(NaCT) (SLC13A5), carry TCA cycle intermediates;
the other two family members, sodium-coupled sulfate
transporters (NaS)1 (SLC13A1) and NaS2 (SLC13A4),
show distinct substrate specificities and mainly trans-
port sulfate, selenite, and thiosulfate (Markovich and
Murer, 2004). The structure and function of the
SLC13 transporter have been reviewed in detail
(Markovich and Murer, 2004; Pajor, 2006, 2014;
Bergeron et al., 2013).
1. Solute Carrier 13A5/Sodium-Coupled Citrate
Transporter.
a. Citrate in energy metabolism. NaCT, encoded by
the SLC13A5 gene, is the sodium-coupled citrate trans-
porter. At physiological pH, NaCT is selective for citrate
over the other TCA cycle intermediates succinate,
malate, and fumarate, which are transported with
lower affinities (Inoue et al., 2002a,b, 2004). NaCT
provides TCA cycle intermediates for the liver and
brain, metabolically active tissue, where NaCT is pre-
dominantly expressed (Figs. 1 and 2). In the liver, NaCT
affects mitochondrial energy production, fatty acid
synthesis, cholesterol synthesis, cytosolic glycolysis,
and gluconeogenesis (Inoue et al., 2004). In the brain,
NaCT is primarily expressed in neural plasma mem-
branes and enables, in concert with NaDC3, an anapler-
otic supply of TCA cycle intermediates (Wada et al., 2006;
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Yodoya et al., 2006). NaCT (also INDY, acronym for “I’m
Not Dead Yet”) was first identified in Drosophila
melanogaster, where mutations in the mammalian
NaCT homolog Indy lead to life span extension
(Rogina et al., 2000). Moreover, IndymRNA was shown
to be downregulated in diet-restricted healthy flies, and
Indy-mutated long-lived flies share several phenotypes
with long-lived caloric-restricted flies. Therefore, NaCT
has been proposed to regulate the aging processes at
least in part by activating an AMP-activated pro-
tein kinase/peroxisome proliferator-activated receptor
g coactivator 1a network (Rogina et al., 2000; Neretti
et al., 2009; Wang et al., 2009; Rogers and Rogina, 2014;
Schwarz et al., 2015).
b. Solute carrier 13A5 genetic variants. SLC13A5
mutations have been described recently to cause early-
onset epileptic encephalopathy (Thevenon et al., 2014;
Hardies et al., 2015; Klotz et al., 2016; Schossig et al.,
2017; Weeke et al., 2017). In contrast, NaCT has not been
directly linked to metabolic disease in humans, and
genome-wide association is lacking. However, in liver
samples of obese, insulin-resistant patients with NAFLD,
SLC13A5 mRNA expression was significantly increased
and associated with hepatic steatosis (von Loeffelholz
et al., 2017b). Importantly, the study is the first hint of
a relationship between NaCT and metabolic disease in
humans.
c. Metabolic phenotype of animal models. The asso-
ciation between NaCT and metabolic disease is well
characterized in animal models (Table 1). Slc13a5
deletion in mice resulted in a metabolic phenotype
resembling caloric restriction (Birkenfeld et al., 2011).
Remarkably, Slc13a5 knockout mice were protected
from high-fat diet (HFD)–induced and aging-induced
obesity, hepatic steatosis, and insulin resistance. The
phenotype was linked to an increase in energy expen-
diture, hepatic mitochondrial biogenesis, and fatty acid
oxidation, and a reduction in hepatic lipogenesis
(Birkenfeld et al., 2011). Consistent with these mouse
data, the knockdown of human SLC13A5 resulted in
Fig. 1. Cellular localization of potential SLC targets for the treatment of metabolic disease. SLC transporters are expressed in the plasma membrane
or intracellular membranes. Of the five presented SLC families, which are displayed in different colors, 13 members have been assessed to exhibit
strong evidence of association with metabolic disease based on human studies and mouse models. The equal shapes of the transporter symbols do not
correspond to the different modes of transport, but the arrows indicate transport direction, for example, whether the transporter is proposed to mediate
influx of its substrates into the cell (SLC5A1, SLC5A2, SLC13A5) or intracellular compartments (SLC25A7, SLC25A8, SLC25A9, SLC30A8), facilitates
both influx and efflux (SLC16A1, SLC16A11, SLC16A13), or acts as an exchanger (SLC25A13, SLC25A20, SLC25A24). The main substrates of the
transporters are indicated next to the transporter symbol, except for SLC16A13, which is not characterized at all concerning substrate specificity and
transport mode.
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lower lipid levels in a hepatocarcinoma cell line (Li
et al., 2015). Moreover, data obtained from rat primary
hepatocytes show an increase in NaCT-mediated
citrate transport after glucagon treatment and addi-
tionally detect cAMP-responsive element-binding protein-
binding sites within the Slc13a5 promotor, suggesting
that Slc13a5 is a cAMP-responsive element-binding
protein–dependent glucagon target that is induced
during periods of fasting and in T2D (Neuschäfer-
Rube et al., 2014).
d. Pharmacological inhibition of sodium-coupled
citrate transporter. Slc13a5deletion andpharmacological
inhibition ameliorate obesity, insulin resistance, and
NAFLD in various model organisms (Birkenfeld et al.,
2011; Shulman and Helfand, 2011; Willmes and
Birkenfeld, 2013; Neuschäfer-Rube et al., 2014;
Huard et al., 2015; Pesta et al., 2015; Brachs et al.,
2016; Willmes et al., 2016, 2018; Rogina, 2017; von
Loeffelholz et al., 2017a). NaCT has therefore been
proposed as a promising target for the prevention and
treatment of metabolic diseases. In rats, the inducible
hepatic Slc13a5 knockdown at onset of the HFD
feeding using 29-O-methoxyethyl chimeric antisense
oligonucleotides improved hepatic glucose production
Fig. 2. Tissue distribution of potential SLC targets for the treatment of metabolic disease. SLC transporters are broadly expressed. The 13 SLCs,
which belong to five families displayed in different colors and were evaluated to have strong potential as targets for the treatment of metabolic disease,
are highly expressed in metabolically active organs such as the liver, kidney, brain, and intestine.
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and insulin sensitivity and protected from NAFLD
(Pesta et al., 2015), thus reproducing the Slc13a5
knockout phenotype. Moreover, hepatic Slc13a5 knock-
down via small interfering RNA improved insulin sensi-
tivity and hepatic triglyceride accumulation in mice
(Brachs et al., 2016). These data led to the development
of specific small-molecule NaCT inhibitors (Pajor and
Randolph, 2007; Sun et al., 2010).
A first proof-of-concept study applied compound 2
(PF-06649298), a small dicarboxylatemolecule that was
discovered using a substrate-based design strategy and
was shown to selectively bind to the NaCT trans-
porter in a competitive and stereosensitive manner.
Impressively, compound 2 led to the potent inhibition of
NaCT-mediated citrate transport in vitro and in vivo
(Huard et al., 2015). In compound 2–treated mice,
glucose intolerance on HFD was completely reversed
and hepatic di- and triglyceride content tended to be
reduced (Huard et al., 2015). This finding suggests an
increase in b-oxidation, supported by a tendency of
higher b-hydroxybutyrate level. To determine the res-
idues that are involved in binding of compound 2,
methods of molecular modeling and site-directed muta-
genesis, transport characterization, and cell surface
biotinylation of the humanNaCT transporter were used
(Pajor et al., 2016). Apparently, residues adjacent to the
putative citrate-binding site (G228, V231, V232, and
G409) affect citrate transport and its inhibition, but also
residues located outside the putative citrate-binding
site (Q77 and T86) might be relevant (Pajor et al., 2016).
Another small-molecule NaCT inhibitor, compound 4a,
is less selective, but also reduced citrate uptake and
moderately ameliorated glucose metabolism in
rodents (Huard et al., 2016). Finally, these data
reveal new mechanistic insights and could guide
SLC13 inhibitor design.
To sum up, cell-based studies and mouse and human
data indicate the potential of targeting the citrate
transporter NaCT to ameliorate metabolic disease.
Notably, small-molecule NaCT inhibitors are already
developed and validated in mouse models of diet-
induced obesity.
2. Therapeutic Potential of Solute Carrier 13
Transporters. Of the five SLC13 family members,
three additional members of the SLC13 family are
marginally linked to metabolic disorders (Table 2) and
will be presented in Emerging Potential of Other Solute
Carrier Target Structures. However, whereas loss of
SLC13A1/NaS1 function in mice causes a complex
phenotype, SLC13A2/NaDC1 and SLC13A3/NaDC3
may be linked to renal disease rather than T2D.
Summarizing the data of the SLC13 sodium-coupled
di- and tricarboxylate cotransporters (Tables 1 and 2),
SLC13A5/NaCT is the most attractive candidate with
which to target obesity and related diseases. SLC13A5
variants have not been linked to human metabolic
diseases in genetic association studies; however, the
Slc13a5 knockout mouse phenotype and studies with
selective small-molecule NaCT inhibitors reflect its
ability to protect from metabolic diseases such as
obesity, fatty liver, insulin resistance, and T2D.
B. Solute Carrier 16: The Monocarboxylate
Transporter Family
Monocarboxylates are major players in cellular en-
ergy metabolism and are substrates as well as products
of anabolic and catabolic pathways in various tissues.
The transport of monocarboxylates in and out of cells is
mediated by monocarboxylate transporters (MCT)
of the SLC16 family, which comprises 14 members
(Halestrap and Price, 1999; Halestrap and Meredith,
2004). The quantitatively most important substrate
is L-lactate. Monocarboxylate transport has not yet
been confirmed for all members of this family. MCT1
(SLC16A1), MCT2 (SLC16A7), MCT3 (SLC16A8), and
MCT4 (SLC16A3) catalyze proton-linked transport
of monocarboxylates, such as L-lactate, pyruvate, and
ketone bodies across the plasmamembrane in and out of
cells (Halestrap andMeredith, 2004). MCT7 (SLC16A6)
appears to export ketone bodies (Hugo et al., 2012),
and MCT11 (SLC16A11) transports pyruvate (Rusu
et al., 2017). Other family members transport larger
hydrophobic monocarboxylates: MCT8 (SLC16A2)
and MCT10 (SLC16A10) transport thyroid hormones
and aromatic amino acids (Visser et al., 2011); MCT9
(SLC16A9) is a carnitine efflux transporter (Suhre
et al., 2011); and MCT12 (SLC16A12) transports crea-
tine (Abplanalp et al., 2013). Natural substrates of four
family members remain unknown. The transporters are
broadly expressed and affect energy metabolism in the
liver, kidney, adipose tissue, heart, muscle, and brain.
Their structure, role, and regulation have been exten-
sively reviewed (Halestrap and Price, 1999; Halestrap
and Meredith, 2004; Halestrap, 2012, 2013; Halestrap
and Wilson, 2012).
1. Solute Carrier 16A1/Monocarboxylate Transporter
1.
a. Monocarboxylates in energy metabolism.
SLC16A1 is ubiquitously expressed and encodes for
MCT1, the first and best-characterized member of the
SLC16 family, which transports L-lactate, pyruvate,
and ketone bodies across the plasma membrane
(Halestrap and Price, 1999) (Figs. 1 and 2). Glycolytic
cells produce lactic acid when oxygen is limited. Lactic
acid is also a substrate for lipogenesis and gluconeo-
genesis in the liver, kidney, and adipose tissue, as well
as a respiratory substrate for tissues such as the heart,
skeletal muscle, and brain. Cells and tissues exhibiting
these anabolic and catabolic pathways express high
levels of MCT1, MCT2, and MCT4, catalyzing
the uptake or efflux of lactic acid (Halestrap and
Meredith, 2004; Halestrap, 2012, 2013; Halestrap and
Wilson, 2012). This lactate shuttle between different
cell types in the same tissue is well described, for
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example, in the muscle, where glycolytic white muscle
fibers secrete lactate via MCT4 that is taken up by
oxidative red muscle fibers via MCT1, and in the
brain, where glycolytic astrocytes secrete lactate via
MCT1 and MCT4 and oxidative neurons take up
lactate via MCT2. Strikingly, lactate is the primary
carbon source in the TCA cycle and therefore of energy
production, highlighting the importance of monocar-
boxylates in energy homeostasis (Hui et al., 2017).
Similar to lactic acid, pyruvate is produced dur-
ing glycolysis, fueling gluconeogenesis or oxidation
in a tissue-specific fashion. The ketone bodies
b-hydroxybutyrate and acetoacetate are produced
during fasting or ketogenic diets and provide energy
for the brain, heart, and skeletal muscle (Halestrap
andMeredith, 2004; Halestrap, 2012, 2013; Halestrap
and Wilson, 2012).
b. Monocarboxylates and cancer. To date,MCT1 has
primarily been linked to the pathogenesis of cancer,
whereas little is known about its potential as target for
other indications (Jones and Morris, 2016; Fisel et al.,
2018). Because lactate metabolism is critical for tumor
growth and MCT1 is an important monocarboxylate
transporter in various cancers, this transporter could
have relevance in anticancer therapy. The role of
monocarboxylate transporters in tumor tissue has been
well described: cancer cells rely on anaerobic glycolysis
to supply energy (Warburg effect) and produce lactate,
which is transported out of the cell via monocarboxylate
transporters (Jones and Morris, 2016). As MCT1,
MCT2, and MCT4 act in a proton-coupled mechanism,
these carriers transport protons out of the cell, thereby
attenuating intracellular acidosis. Secreted lactate is
transported by SLC16 proteins into neighboring cells
that rely on oxidative phosphorylation. Lactate shut-
tling in tumor tissue between cells with different energy
needs is mediated by MCT1, MCT2, and MCT4. There-
fore, these transporters may serve as tumor markers
and drug targets. Of note, the MCT1 inhibitor AZD3965
is in phase I clinical testing (www.clinicaltrials.gov) as
an anticancer drug. Multiple studies validated the
efficacy of the therapeutic principle in cancer cell lines
and an in vivo model of xenograft tumors, confirming
the inhibition of bidirectional monocarboxylate trans-
port by AZD3965 and illustrating reduced glycolytic
activity and consequently reactivation of oxidative
phosphorylation to maintain cell survival (Bola et al.,
2014; Polanski et al., 2014; Beloueche-Babari et al.,
2017).
c. Solute carrier 16A1 genetic variants. Using
AZD3965 in treatingmetabolic disease is not an obvious
choice because genetic proof of an association between
SLC16A1 gene locus and diet-induced obesity and T2D
in human subjects is lacking. Nevertheless, MCT1
is linked to metabolic traits in humans and in mice
(Table 1). In two independent studies, homozygous and
heterozygous SLC16A1 loss-of-function gene mutations
were linked to recurrent, severe ketoacidosis in humans
(van Hasselt et al., 2014; Balasubramaniam et al.,
2016). Ketoacidosis is caused by excess circulating
ketone bodies in the face of insulinopenia and is
generally a severe complication of diabetes (Nuttall,
1965; Winegrad and Clements, 1971). Targeted exome
sequencing in an index patient and her family members
revealed nine rare SLC16A1 variants (van Hasselt
et al., 2014). Subsequent analysis of more patients with
unexplained ketoacidosis identified seven additional
variants, including six truncating mutations likely
resulting in loss of protein function. Mutations were
correlated with disease severity and MCT1 protein
expression and activity. Therefore, MCT1-mediated
transport of ketone bodies into extrahepatic tissues
may be essential in preventing acidosis during periods
of high ketone body turnover (van Hasselt et al., 2014).
Although heterozygous SLC16A1 mutations can result
in clinical symptoms, heterozygous relatives of patients
did not develop ketoacidosis. Additional environmental
and/or genetic factors may exacerbate symptoms. The
hypothesis is supported by the symptom-free intervals
seen in the patients (van Hasselt et al., 2014).
Promotor-activating SLC16A1 mutations have been
identified in patients with exercise-induced hyperinsu-
linemia, a condition characterized by periods of severe
hypoglycemia after physical exercise and linked to
syncope (Meissner et al., 2001; Otonkoski et al., 2003,
2007). Excess SLC16A1 expression in pancreatic b-cells
may increase circulating insulin via a mechanism link-
ing increased pyruvate uptake and catabolism to higher
ATP levels and insulin secretion (Otonkoski et al.,
2007). MCT1-related pathophysiology in humans
deserves further evaluation because MCT1 inhibition
may be beneficial in treating exercise-induced hyper-
insulinemia, but could also promote ketoacidosis.
d. Metabolic phenotype of animal models.
Exercise-induced hyperinsulinemia and hypoglycemia
were reproduced in transgenic mice with b-cell–specific
Slc16a1 overexpression (Pullen et al., 2012). Genetic
Slc16a1 deletion further suggested that the transporter
affects whole-body energy homeostasis (Lengacher
et al., 2013). Slc16a1 null mutation in mice is embry-
onically lethal, whereas heterozygous animals develop
normally. Interestingly, heterozygous Slc16a1 knock-
out mice are resistant to diet-induced obesity and show
less insulin resistance and hepatic steatosis compared
with littermate controls. Reduced weight gain was
associated with decreased hepatic and white adipose fat
accumulation, potentially mediated by AMP-activated
protein kinase secondary to reduced substrate avail-
ability (Carneiro et al., 2017). Metabolic changes in
MCT-deleted mice support the concept that monocar-
boxylate transport is important for metabolic control.
A putative role of MCT1 in metabolic disease is also
supported by increased brain expression in diet-induced
obese and genetically obese ob/ob and diabetic db/db
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mice (Pierre et al., 2007). Chronic hyperglycemia elicits
a similar response in rat brains (Canis et al., 2009),
which governs energy homeostasis. Slc16a1 was also
upregulated in mouse liver, kidney, and small intestine
by the peroxisome proliferator-activated receptor a
(PPARa), an important mediator of lipid catabolism
that is linked to obesity (König et al., 2008).
In summary, multiple publications implicate mono-
carboxylate transporters in body weight regulation
(Carneiro and Pellerin, 2015). Despite the metabolic
phenotype of Slc16a1 haploinsufficient mice and al-
tered Slc16a1 expression in obesity, MCT1 was never
discussed as a metabolic treatment target, and no
genetic evidence has been described in human GWAS.
However, clinical testing of theMCT1 inhibitorAZD3965
holds promise.
2. Solute Carrier 16A11/Monocarboxylate Trans-
porter 11.
a. Discovery of a novel type 2 diabetes risk gene.
A hitherto unnoticed and uncharacterized member of
the SLC16 family has recently attracted interest in
metabolic research: MCT11, the transporter encoded by
the SLC16A11 gene. SLC16A11 sequence variants
predicted T2D risk in a GWAS. The SIGMA type 2
diabetes consortium analyzed SNPs in Mexicans
and other Latin Americans and identified a haplotype
associated with T2D (Williams et al., 2014). The
risk haplotype includes one silent and four missense
SNPs in the SLC16A11 gene. Three of four amino
acid–substituting SNPs are predicted to be tolerated
(rs117767867, rs75418188, rs75493593), whereas one
SNP (rs13342692) is predicted to be damaging. The risk
to develop T2D increases by approximately 20% per
haplotype copy. Subjects carrying the risk haplo-
type develop T2D on average 2.1 years earlier and at
0.9 kg/m2 lower body mass index (BMI) than non-
carriers. The stronger association in younger and leaner
individuals may reflect a role of MCT11 in T2D
pathogenesis independently of adiposity. Remarkably,
the risk haplotype is present in 48% of Native American
and in 12% of Asian populations, but rare or absent in
European or African samples. Gene expression analysis
in human tissues illustrated highSLC16A11 expression
in the liver, salivary glands, and thyroid (Fig. 2). More-
over, humanMCT11 protein localizes to the endoplasmic
reticulum (Fig. 1), but only marginally to the plasma
membrane (Williams et al., 2014; Rusu et al., 2017).
Metabolite profiling of SLC16A11-expressing HeLa cells
showed a substantial increase in triacylglycerol (TAG)
and a modest increase in diacylglycerol (DAG) concen-
trations, whereas lysophosphatidylcholine, cholesterol
ester, and sphingomyelin lipid concentrations were de-
creased. Perturbed lipidmetabolism, especially TAGand
DAG accumulation, promotes insulin resistance and
T2D. Possibly, MCT11 modulates T2D risk in part
through actions on hepatic lipid metabolism.
b. Solute carrier 16A11 genetic variants. The find-
ings regarding theSLC16A11 riskhaplotype inMexicans
(Williams et al., 2014) inspired subsequent investiga-
tions. The SLC16A11 polymorphism rs13342692, pre-
dicted to be the crucial SNP in the riskhaplotype,was not
significantly associated with T2D in Mayas (Lara-Riegos
et al., 2015). However, the study presented significant
associations between rs13342692 and plasma insulin
levels and homeostasis model assessment for insulin
resistance in nonobese nonaffected risk allele carriers,
implicating a higher susceptibility tometabolic disorders
for risk allele carriers. Additionally, SLC16A11 risk
haplotype carriers exhibit decreased insulin action, and
transaminase levels are increased in carriers with di-
abetes (Almeda-Valdes et al., 2019). The diabetes risk
haplotype was further confirmed in a Hispanic/Latino
cohort in the United States with an association to diabe-
tes in the Mexican-American, but not in non-Mexican
Hispanic/Latino groups (Hidalgo et al., 2019).
In American Indians, carriers of the SLC16A11
rs75493593 risk allele with a BMI , 35 kg/m2 showed
an increased risk for T2D and a decreased T2D risk with
higher BMI (Traurig et al., 2016). Similarly, a longitu-
dinal follow-up on the BMI and diabetes status of
individuals yielded a higher hazard ratio in the leanest
BMI and vice versa. The longitudinal data set also
raised the question of whether rs75493593 allele car-
riers with lower BMI are prone to T2D, or whether they
lose weight as a consequence of T2D onset. In one study
cohort, individuals carrying the risk allele lost more
weight after T2D onset, highlighting the possibility that
additional factors influence the association between
BMI and the risk allele in T2D. However, the finding
was not reproduced in another study cohort (Traurig
et al., 2016). Individuals carrying the risk allele dis-
played increased carbohydrate and reduced lipid oxida-
tion rates (Traurig et al., 2016). Differential levels of
lipidmetabolites have also been observed inSLC16A11-
expressing HeLa cells (Williams et al., 2014). Reduced
mitochondrialb-oxidation due to reducedmitochondrial
density with subsequent DAG accumulation predispo-
ses development of insulin resistance and T2D (Samuel
et al., 2010; Birkenfeld and Shulman, 2014; Goedeke
et al., 2019). Therefore, lower lipid oxidation rates in
a SLC16A11 risk allele carrier could conceivably confer
increased T2D risk. The SLC16A11 risk allele also
affected expression of the adjacent RNASEK gene,
encoding for the ribonuclease K. The interaction
decreases RNASEK expression in the adipose tissue,
muscle, and whole blood of risk allele carriers. Possibly,
both genes contribute to the phenotypic associations
observed in this study. Because altered hepatic and
adipose RNASEK expression were not detected in
another study of risk haplotype carriers (Rusu et al.,
2017), the significance of this observation is unclear.
c. Potential causal role of monocarboxylate trans-
porter 11. Recent data showed that the SLC16A11
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diabetes risk haplotype affects MCT11 by reducing its
mRNA expression, but also by inhibiting transporter
translocation to the plasma membrane (Rusu et al.,
2017). Specifically, SLC16A11 gene expression was
reduced in liver samples taken from carriers of the risk
haplotype in a gene dose-dependent manner. Addition-
ally, the authors show that the four coding variants
associated with T2D risk reduce cell-membrane expres-
sion of the transporter. Diminished interaction with the
chaperone protein basigin may have contributed to
reduced transporter activity. Finally, to analyze the
consequences of reduced MCT11 function, the authors
knocked down SLC16A11 in primary human hepato-
cytes and observed that intracellular acylcarnitines,
DAGs and TAGs, were significantly increased. DAGs
and ceramides mediate insulin resistance via activation
of novel protein kinases and subsequent serine phos-
phorylation of the insulin receptor and/or the insulin
receptor substrate 1 (Birkenfeld and Shulman, 2014;
Petersen et al., 2016). Thus, MCT11 may affect cellular
fatty acid and lipid metabolism, thereby promoting
insulin resistance and T2D. However, the exact molec-
ular pathway remains unknown. Reduced cell surface
localization of T2D risk variants may be critical in T2D
pathogenesis. Despite this, only a very small portion
of the wild-type protein localizes to the plasma mem-
brane, and it is unclear whether MCT11 serves as an
intracellular and/or plasma membrane transporter.
MCT11 may translocate to the plasma membrane in
physiological conditions requiring its transport activity.
Furthermore, other SLC16 family members also
transport pyruvate, and additional substrates may
be transported by MCT11. Perhaps some substrates
are specifically transported by MCT11 under partic-
ular physiological or metabolic conditions. If so,
compensatory substrate transport by other monocar-
boxylate transporter may not suffice, when MCT11
function is reduced through genetic risk variants.
Clearly, cellular localization and the regulation of
MCT11 in health and disease require further study.
d. Metabolic phenotype of animal models. The first
data on aMCT11-deficientmousemodel were published
in 2019 (Zhao et al., 2019b). Whereas constitutive
Slc16a11 knockout did not result in severe metabolic
consequences, even in animals fed HFD, reconstitution
of knockout mice with mutant Slc16a11 in the liver
using a liver-specific adeno-associated virus resulted in
a metabolic phenotype. The phenotype comprised in-
creased blood and liver triglycerides and reduced
glucose tolerance and insulin resistance. Hepatic
reconstitution of mutant Slc16a11, but not of the wild-
type Slc16a11, results in Lipin-1 upregulation. There-
fore, the observed increase in liver triglycerides may
have been mediated through Lipin-1, an enzyme in-
volved in triglyceride synthesis. In contrast to previous
studies indicating that reduced MCT11 function pro-
motes T2D risk (Rusu et al., 2017), the authors proposed
that gain-of-function mutations in Slc16a11 foster
T2D. However, functional characterization of mutant
Slc16a11 was not shown, and hepatic reconstitution
with wild-type Slc16a11 also resulted in lipid accumu-
lation. Although these findings suggest that MCT11
contributes to hepatic lipid metabolism, they do not
prove that gain of function explains the observed
detrimental metabolic phenotype in their MCT11
mouse model.
In conclusion, although the detailed mechanism of
MCT11 action in the development of T2D is still not
clear, the causal role of MCT11 in T2D is strongly
supported by genetic association combined with in vitro
genetic and functional data predicting the loss of pro-
tein function to be disease promoting. Thus, enhancing
MCT11 function may hold “the promise as a potential
therapy for T2D” (Stadler and Farooqi, 2017). Thera-
peutic approaches could increase gene expression or
protein level, restore MCT11 protein interaction with
basigin for correct plasma membrane localization, or
increase transport activity of the protein.
3. Solute Carrier 16A13/Monocarboxylate Trans-
porter 13. In parallel with SLC16A11, SLC16A13,
encoding for MCT13, was identified as another locus
of the SLC16 family associated with T2D. The
SLC16A13 polymorphism rs312457 was linked to T2D
in a recent Japanese GWAS (Hara et al., 2014). The
associations were not confirmed in Europeans. Differ-
ences in linkage disequilibrium distribution between
populations may have contributed to the discrepancy
(Hara et al., 2014). Strictly, MCT13 first appeared in
another study: the SLC16A11 risk haplotype identify-
ing GWAS published in the same year described an
association at chromosome 17p13.1 spanning the two
adjacent located genes SLC16A11 and SLC16A13, but
localized the strongest association signal to the
SLC16A11 gene (Williams et al., 2014). Therefore, both
GWAS highlight a potential role of MCT13 in the
development of T2D. Yet, the function and biology of
MCT13 are unknown. MCT13 is located at the mem-
brane of the Golgi apparatus (Fig. 1) and highly
expressed in the liver, kidney, and intestine (Fig. 2)
(Williams et al., 2014). Compared with MCT11, GWAS
highlighting a potential role of MCT13 in metabolic
disease are limited, and substrate(s) and physiological
function of the protein are not characterized at all
(Table 1). One mouse study showed an upregulation of
Slc16a13 gene expression in the small intestine after
treatment with a PPARa agonist (Hirai et al., 2007).
Because PPARa is a key regulator of hepatic lipid
metabolism, these mouse data are in line with the
notion that MCT13 regulates lipid metabolism and that
MCT13 deregulation may contribute to lipid-induced
insulin resistance and T2D.
Finally, functional studies are necessary to under-
stand if and how the MCT13 transporter could be
modulated to counteract T2D development. Whether
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activation, as proposed for MCT11, or inhibition could
improve metabolic disease is unknown. Because the
SLC16A13 gene has been directly linked to T2D in
humans, the transporter should be investigated further.
4. Therapeutic Potential of Solute Carrier 16
Transporters. Various studies highlight the role of
SLC16 family members in physiology and pathophysiol-
ogy. The largest data sets exist for the best-characterized
transporters SLC16A1/MCT1, SLC16A3/MCT4, and
SLC16A7/MCT2. However, few genetic studies have
linked thesemonocarboxylate transporters to metabolic
disease. More detailed knowledge concerning expres-
sion pattern, substrate specificity, and function in
health and disease as well as biochemical andmolecular
mechanisms is required to judge whether SLC16 family
members are potential drug targets for metabolic
disease. MCT1 is primarily discussed as a target in
cancer therapy, and human genetic data linking
SLC16A1 genetic variants to metabolic disease are
scarce, although mouse data are convincing. SLC16A13
has to date only been identified in one GWAS. Addi-
tional genetic studies and a valid mouse model are
needed to verify the link between MCT13 function and
T2D. SLC16A11 has been directly linked to human T2D
in substantial GWAS, and the MCT11 transporter has
also partially been functionally characterized in disease
models (Table 1). Currently, MCT11 is the most attrac-
tive candidate to target for the treatment of metabolic
disease. Additional SLC16 transporters such as SLC16A3/
MCT4, SLC16A9/MCT9, and SLC16A10/MCT10 have
been linked to diabetic nephropathy, gout, and NAFLD,
respectively (Table 2). Detailed information of thera-
peutic potential of these SLC16 family members is
provided in Emerging Potential of Other Solute Carrier
Target Structures.
C. Solute Carrier 25: The Mitochondrial
Carrier Family
The SLC25 gene family is the largest of the SLC
transporter superfamily, comprising 53 members with
highly diverse substrate specificities and tissue expres-
sions. SLC25 genes encode mitochondrial carriers that
are mostly localized in the inner mitochondrial mem-
brane (Fig. 1). Their substrates vary widely in structure
and size from small ions like H1 to the larger molecules
such as ATP or coenzyme A (Palmieri, 2004). For
many SLC25 family members, substrate specificities
remain unknown (Palmieri, 2013). Based on the sub-
strates transported, mitochondrial carriers can be
classified as carriers for amino acids, carboxylates, keto
acids, nucleotides, dinucleotides, coenzymes, and other
substrates. Carriers of the SLC25 family are further
divided into subfamilies, which are characterized
by distinctive structural features, substrate specificity,
mode of transport, and kinetic properties. Functionally,
SLC25 transporters have been implicated in diverse
metabolic pathways, including oxidative phosphorylation,
TCA cycle, fatty acid oxidation, gluconeogenesis, lipo-
genesis, ketone body production and utilization, urea
synthesis, amino acid degradation, regulation of nucle-
otide and deoxynucleotide pools in the mitochondrial
matrix, heat production, and many more (Palmieri,
2004, 2013; Palmieri and Monne, 2016). The SLC25
family is associated with human diseases, highlighting
the essential function of solute transport through the
inner mitochondrial membrane in linking mitochon-
drial and cytosolic metabolism (Palmieri, 2004, 2013;
Palmieri and Monne, 2016).
A subfamily of mitochondrial carriers includes the
uncoupling proteins (UCPs) that play an important role
in energy homeostasis. It consists of six members, of
which UCP1 (SLC25A7), UCP2 (SLC25A48), and UCP3
(SLC25A9) are the most prominent. Generally, sub-
strate oxidation is coupled to ATP formation. Oxidative
phosphorylation generates a proton gradient by the
respiratory chain across the inner mitochondrial mem-
brane, which is used to generate ATP fromADP through
flowback of the protons mediated by ATPase. UCPs can
uncouple ATP production from mitochondrial respira-
tion, thereby dissipating energy as heat (Schrauwen
et al., 1999a). UCP1, UCP2, and UCP3 are mitochon-
drial proton transporters (Fig. 1) that are linked to
obesity and T2D in both human studies and rodent
models (Schrauwen et al., 1999a; Dalgaard and Pedersen,
2001; Hesselink et al., 2003; Langin, 2003; Jia et al.,
2009; Dalgaard, 2011; Souza et al., 2011; Brondani
et al., 2012; Liu et al., 2013; Busiello et al., 2015;
Giralt and Villarroya, 2017; Ost et al., 2017; Sreedhar
and Zhao, 2017) (Table 1).
1. Solute Carrier 25A7/Uncoupling Protein 1.
a. Mitochondrial uncoupling and thermogenesis.
UCP1, also known as thermogenin, is encoded by the
SLC25A7 gene and is expressed in brown adipose tissue
(Fig. 2). In contrast to white adipose tissue, which is
the primary site of energy storage, brown adipose
tissue contains large amounts ofmitochondria. Through
uncoupled mitochondrial respiration, brown adipose
tissue regulates thermogenesis. UCP1 is responsible
for the mitochondrial proton leak (Nicholls et al., 1978)
and is the UCP, which mediates energy dissipation as
heat (Golozoubova et al., 2001; Nedergaard et al., 2001).
The term “mitochondrial proton leak” defines a non-
ATP–consuming process that takes place when inner
mitochondrial membrane proton conductance is in-
creased and the generated proton gradient is insuffi-
cient such that oxygen consumption is uncoupled from
ATP production. Because mitochondria of brown adi-
pose tissue are particularly permeable to protons, pro-
ton leakage in this tissue directly dissipates energy as
heat, explaining the thermogenic activity of brown
adipose tissue (Nicholls and Locke, 1984). Brown
adipose tissue thermogenesis plays a key role in the
development of obesity in animal models (Rothwell and
Stock, 1979; Lowell et al., 1993; Feldmann et al., 2009;
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Kajimura and Saito, 2014) and in humans (Nedergaard
et al., 2007; Cypess et al., 2009; Saito et al., 2009; van
Marken Lichtenbelt et al., 2009; Kiefer, 2017; Leitner
et al., 2017).
b. Solute carrier 25A7 genetic variants. Numerous
human studies have linked SLC25A7 polymorphisms
to obesity and T2D (Table 1). Most association stud-
ies focused on the rs1800592 polymorphism in the
SLC25A7 promotor region that has been associated with
reduced SLC25A7 mRNA expression in obese subjects
(Esterbauer et al., 1998). The datasuggest that reduced
protein function increases susceptibility to metabolic
disease. However, findings across more than 30 human
genetic studies, including subjects from different popula-
tions worldwide, varied. Some studies showed associa-
tions between one or more SLC25A7 polymorphisms with
obesity, diabetes, or other metabolic syndrome character-
istics.Others did not showassociations betweenSLC25A7
polymorphisms and metabolic traits (Brondani et al.,
2012). Data remain conflicting regarding the effect of the
allelic variants. For example, whereas the G-allele of the
rs1800592 polymorphism (-3826A.G) was significantly
associated with increased BMI (Chathoth et al., 2018),
another study reported that G-allele carriers had lower
body weight and fat mass and homozygous G-allele
carriers had lower frequency of T2D compared with
patients carrying theA-allele (Nicoletti et al., 2016). Other
studies did not detect any association between the
SLC25A7 polymorphism and BMI, obesity, or T2D risk
(de Souza et al., 2013; Brondani et al., 2014a,b).
c. Metabolic phenotype of animal models. The idea
that UCP1 dysfunction promotes obesity has been
extensively investigated in mouse models. As early as
1978, defects in thermogenesis were demonstrated in
genetically obese ob/ob mice that were cold-sensitive
(Himms-Hagen and Desautels, 1978). Transgenic mice
with the primary deficiency of brown adipose tissue
lacking UCP1 became obese at a young age in the
absence of hyperphagia. This finding indicates that
brown adipose tissue–deficient mice have increased
metabolic efficiency (Lowell et al., 1993). However,
Slc25a7 knockout mice were cold-sensitive, indicating
defective thermoregulation, but the animals did not
become obese on either a standard diet or HFD. Loss of
UCP1 could therefore be compensated in part by UCP2
that is induced in brown fat of UCP1-deficient mice.
Other signals that are involved in the regulation of body
weight could also contribute to the finding (Enerbäck
et al., 1997).
Transgenic mice with Slc25a7 expression in white
adipose tissue exhibit markedly reduced HFD-induced
obesity in association with a comparable total oxidative
capacity in white and brown adipose tissue (Kopecky
et al., 1995; Kopecký et al., 1996a,b; Baumruk et al.,
1999). Ectopic Slc25a7 expression in epididymal fat
through adenovirus vector injection improves glucose
tolerance and decreases food intake in both diet-induced
and genetically obese mouse models (Yamada et al.,
2006). Transgenic Slc25a7 expression in mouse skeletal
muscle increased muscle oxygen consumption dramat-
ically and protected from diet-induced obesity, im-
proved insulin sensitivity, and increased metabolic
rate at rest and with exercise (Li et al., 2000). In
a genetic obese mouse model, tetracycline-inducible
Slc25a7 expression in skeletal muscle lowered body
weight, increased oxygen consumption, improved glu-
cose tolerance, and unexpectedly lowered blood pres-
sure (Gates et al., 2007).
d. Mitochondrial uncoupling to treat metabolic
disease. The so-called browning of white adipose tis-
sue has received much attention in recent years. Today,
it is known that UCP1 can be induced in white fat cells
by cold as well as pharmacological, nutritional, and
endogenous stimuli (Ost et al., 2017). Although the
presence of brown fat depots in adult humans was
questioned, SLC25A7-expressing adipocytes in adults
were shown inmultiple studies and also associated with
lower mass and/or activity in obese and older subjects
(Cypess et al., 2009; Saito et al., 2009; van Marken
Lichtenbelt et al., 2009; Virtanen et al., 2009; Leitner
et al., 2017).
Obesity treatment aims to reduce energy intake and/
or increase energy expenditure. Therapeutic interven-
tion reduces energy intake either by affecting satiety
centers in the brain such as sibutramine (Bray et al.,
1999; James et al., 2000; Ryan, 2000) and glucagon-like
peptide 1 receptor agonists (O’Neil et al., 2018), or by
decreasing the efficiency of intestinal absorption such
as orlistat (Sjöström et al., 1998). Chemical agents such
as 2,4-dinitrophenol or carbonyl cyanide p-(trifluorome-
thoxy) phenylhydrazone increase energy expenditure
by uncoupling mitochondrial oxidative respiration.
However, life-threatening side effects limit the use of
such compounds (Parascandola, 1974). More recently,
liver-specific mitochondrial protonophores, called
controlled-release mitochondrial protonophores, pro-
duce mild hepatic mitochondrial uncoupling, amelio-
rated hepatic steatosis, and insulin resistance in
a HFD-fed rat model and steatohepatitis in a rat model
of nonalcoholic steatohepatitis (Perry et al., 2015). The
treatment also prevented hepatic steatosis, insulin
resistance, and T2D in lipodystrophic mice (Abulizi
et al., 2017). Given this proof of concept, mitochondrial
uncoupling targetingUCP1 received renewed interest to
modulate whole-body energy homeostasis and to treat
obesity and related metabolic diseases (Ost et al., 2017).
Taken together, mouse and human studies indicate
an essential role of UCP1 in body weight regulation,
T2D, and arterial hypertension. Therefore, modulation
of brown adipose tissue thermogenesis to increase
energy expenditure could be an effective strategy
against obesity. Reduced SLC25A7 gene expression in
obese subjects indicates reduced transporter activity as
causative for the related disease phenotypes, andmouse
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models clearly support the idea of protection from diet-
induced obesity due to ectopic Slc25a7 expression.
Most importantly, a very recent publication identified
the chemical compound linifanib as a potent inducer
of UCP1 expression in primary inguinal adipocytes
in vitro and in vivo (Zhao et al., 2019a). Of note, linifanib
(ABT-869), an orally bioavailable, small-molecule re-
ceptor tyrosine kinase inhibitor, has been reported to
exhibit potent antiangiogenic and antitumor effects in
preclinical studies and is currently undergoing phase
III trials (McKeegan et al., 2015; Horinouchi, 2016).
Thus, additional research on the effect of a specific
UCP1 activator in the context of obesity seems to be
enormously promising, and existing linifanib preclini-
cal studies could facilitate its application in obese
subjects. In contrast to existing anti-obesity drugs, an
UCP1 activator might have additional metabolic bene-
fits regarding diabetes and hypertension. However, the
safety profile will need to be carefully studied due to the
possibility of hyperthermia, and the parallel effect of
receptor tyrosine kinase inhibition in the patients must
be critically investigated.
2. Solute Carrier 25A8/Uncoupling Protein 2 and
Solute Carrier 25A9/Uncoupling Protein 3.
a. Physiological functions irrespective of mitochon-
drial uncoupling. UCP2, encoded by SLC25A8, was
identified in 1997 as novel mitochondrial uncoupling
protein that, unlike UCP1, is widely expressed in
human tissues (Fleury et al., 1997; Gimeno et al.,
1997) (Fig. 2). UCP3, product of the SLC25A9 gene
predominantly expressed in skeletal muscle, was iden-
tified shortly thereafter (Boss et al., 1997; Lowell, 1999)
(Fig. 2). Because the two genes are localized adjacent on
chromosome 11, they may result from an ancestral gene
duplication. In contrast to UCP1, the physiological
functions of UCP2 and UCP3 are less well defined and
may include the export of fatty acids or fatty derivates
from the mitochondrial matrix (Moore et al., 2001;
Goglia and Skulachev, 2003; Schrauwen et al., 2003;
Schrauwen andHesselink, 2004; Bouillaud et al., 2016).
Other physiological functions involve antioxidantmech-
anisms, which may maintain the balance between
reactive oxygen species production and clearance. A
possible side effect of proton leaks is a higher flow rate
through the electron–transport chain, and therefore
a decrease in the half-life of radical intermediates,
which can donate its electron to oxygen and create
reactive oxygen species (Dalgaard and Pedersen, 2001).
UCP2 and UCP3 might dissipate the proton gradient to
prevent reactive oxygen species generation, thereby
regulating oxidative stress and cell signaling (Echtay
et al., 2002;Mailloux andHarper, 2011; Bouillaud et al.,
2016).
b. Solute carrier 25A8 and solute carrier 25A9 genetic
variants. The first SLC25A8 and SLC25A9 gene poly-
morphisms were identified in Danish persons with
obesity (Urhammer et al., 1997, 1998). In the last two
decades, allelic variants of the genes have been studied
in different populations (Table 1). Dalgaard and
Pedersen (2001) and Dalgaard (2011) reviewed physio-
logic al functions of both transporters and known poly-
morphisms that are associated with obesity and
T2D. Three common SLC25A8 polymorphisms are well
studied in humans: the promoter variant rs659366
(-866G.A), the missense variant rs660339 (c.164C.T;
p.A55V), and a 45-bp insertion–deletion polymorphism
in the 39 untranslated region. The rs659366 pro-
moter minor A-allele most likely directs higher rates
of transcription from the SLC25A8 promoter compared
with the G-allele (Dalgaard, 2011). Conflicting studies
show the polymorphism to be associated with a reduced
risk of obesity (Esterbauer et al., 2001; Jun et al., 2009),
but also with increased obesity prevalence (Dhamrait
et al., 2004; Ochoa et al., 2007; Kring et al., 2008).
Several studies revealed no associations, suggesting
that UCP2 has only a modest effect, if any, on the
development of obesity (Dalgaard, 2011). Similarly,
human data on b-cell function and T2D are partially
conflicting. Heterozygous SLC25A8 mutations were
reported in patients suffering from congenital hyper-
insulinemia (Gonzalez-Barroso et al., 2008). Because
SLC25A8 null mutations are related to hyperinsuline-
mia, the A-allele of the rs659366 variant, resulting in
increased gene expression, is expected to show associ-
ation with decreased b-cell function and ultimately with
T2D (Dalgaard, 2011). Indeed, decreased glucose-
stimulated insulin secretion was observed in two stud-
ies (Sesti et al., 2003; Sasahara et al., 2004), and
decreased basal insulin secretion was reported among
A-allele carriers (Esterbauer et al., 2001). Others did
not reproduce the associations (Dalgaard et al., 2003;
Sesti et al., 2003; D’Adamo et al., 2004; Ji et al., 2004;
Bulotta et al., 2005). Moreover, both alleles of the
rs659366 variant were associated with T2D (Sasahara
et al., 2004; Lyssenko et al., 2005; Gable et al., 2006).
Both increased risk of hypertension (Ji et al., 2004) as
well as decreased risk of coronary artery disease in
subjects with T2D (Cheurfa et al., 2008; Palmer et al.,
2009) have been reported to be associated with the
A-allele of the rs659366 polymorphism. Given the
conflicting data, larger samples with well-characterized
participants are required to detect the true effect of an
identified variant (Dalgaard, 2011). A more recent meta-
analysis of 42 studies evaluated associations of the three
commonSLC25A8 gene polymorphisms with overweight
and obesity: the T-allele of rs660339 polymorphism was
associated with an increased risk of obesity, the A-allele
of the rs659366 promotor polymorphism protected from
obesity, and the 45-bp insertion/deletion polymorphism
was not associated with obesity susceptibility (Zhang
et al., 2014).
The promoter variant rs1800849 (-55C.T) of the
SLC25A9 gene is common and well-studied (Cassell
et al., 2000; Dalgaard et al., 2001a,b; Berentzen et al.,
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2005). The T-allele results in increased SLC25A9
expression in skeletal muscle and may raise resting
energy expenditure (Schrauwen et al., 1999c; Kimm
et al., 2002). Low resting energy expenditure promotes
weight gain. Indeed, one study revealed a negative
correlation between SLC25A9 expression and BMI
(Schrauwen et al., 1999b). Furthermore, the T-allele
was associated with reduced BMI, increased high-
density lipoprotein–cholesterol levels (Schrauwen
et al., 1999c; Liu et al., 2005; Hamada et al., 2008),
reduced T2D risk, and higher plasma total cholesterol
and low-density lipoprotein cholesterol concentrations
(Meirhaeghe et al., 2000). However,multiple studies did
not observe associations between the rs1800849 poly-
morphism and metabolic rate, obesity, BMI, insulin
secretion, or T2D (Walder et al., 1998; Dalgaard et al.,
2003; Berentzen et al., 2005; Ochoa et al., 2007; Hsu
et al., 2008). Some showed a reverse association of the
T-allele with higher BMI and waist circumference
(Otabe et al., 2000; Herrmann et al., 2003; Lindholm
et al., 2004). Jia et al. (2009) provided a comprehensive
overview of SLC25A9 polymorphisms and noticed the
discrepancies between studies that might be explained
partially by influences of adjacent loci in the same
haplotype, as well as the exclusion of key lifestyle
factors in the statistical analyses.
The potential role of both genes in metabolic disease
is further supported by studies indicating that expres-
sion of SLC25A8 and SLC25A9 predicts diabetes onset
in humans. Variation in the SLC25A8-SLC25A9 gene
cluster is associated with an increased T2D risk (Gable
et al., 2006). Moreover, reduced UCP3 protein levels
were reported in individuals with prediabetes and
T2D (Schrauwen et al., 2006). Recent meta-analyses
detected significant associations between the SLC25A8
and SLC25A9 polymorphisms and BMI, obesity, and
T2D (de Souza et al., 2013; Brondani et al., 2014a,b).
However, associations markedly differed between dif-
ferent populations; a recent cross-sectional study of
European adolescents failed to identify any association
between SLC25A8 or SLC25A9 variants and adiposity,
whereas the C-allele of the SLC25A7 rs6536991 intron
variant was associated with a lower risk of overweight
(Pascual-Gamarra et al., 2019). Mechanisms and phe-
notypes are not clear to date, and, as for every GWAS,
interindividual differences, including ethnic, lifestyle,
environmental and genomic factors, and nutritional
characteristics, result in different effects of described
SLC25A8 and SLC25A9 polymorphisms on obesity and
related phenotypes. These factors could interfere
with UCP2 and UCP3 physiology and pathophysiol-
ogy. Regarding limited consistency between studies,
further human studies and functional characterization
of both transporters could help to solve the unanswered
questions.
c. Metabolic phenotype of animal models. Mouse
studies support links between UCP2 and UCP3 and
obesity and related disorders, but also present varying
phenotypes. Increased Slc25a8mRNA levels have been
observed in obesity-resistant A/J mice compared with
obesity-prone B6mice. Moreover, HFD inducedSlc25a8
in white adipose tissue. The findings suggest that
SLC25A8 might play a role in the development of
hyperinsulinemia and obesity (Fleury et al., 1997).
UCP2 does not seem to regulate body weight or cold-
induced thermogenesis in mice (Arsenijevic et al., 2000;
Zhang et al., 2001). UCP2-deficient mice exhibited
increases in insulin and lower blood glucose levels.
Furthermore, pancreatic islets lacking UCP2 feature
increased ATP levels and increased insulin secretion.
The finding indicates that UCP2 negatively regulates
glucose-stimulated insulin secretion possibly linking
obesity and b-cell dysfunction. Indeed, UCP2 is upregu-
lated in obese ob/ob mice, and UCP2 deficiency mark-
edly improved their diabetic phenotype (Zhang et al.,
2001). However, contrary to results in UCP2-deficient
mice of mixed 129/B6 strain background (Zhang et al.,
2001), glucose-stimulated insulin secretion in UCP2-
deficient islets of congenic mouse strains was signifi-
cantly decreased, and these mice also did not become
diabetic (Pi et al., 2009). Increased oxidative stress in
UCP2-deficient mice may contribute to declining b-cell
function, but overall, the pathophysiological role of
UCP2 is unclear.
UCP3 deficiency in mice does not affect body weight
regulation, exercise tolerance, fatty acid oxidation, or
cold-induced thermogenesis. Yet, reactive oxygen spe-
cies are more abundant in skeletal muscle, indicating
that UCP3 protects from oxidative stress (Gong et al.,
2000; Vidal-Puig et al., 2000). Transgenic mice over-
expressing human SLC25A9 in skeletal muscle are
hyperphagic. Nevertheless, body weight and adipose
tissue mass are reduced, together with lower fasting
plasma glucose and insulin levels and an increased
glucose clearance rate (Clapham et al., 2000;
Horvath et al., 2003). Strikingly, UCP2 and UCP3
deficiency in mice is associated with increased pro-
duction of reactive oxygen species that is known to be
involved in insulin resistance (Houstis et al., 2006).
Therefore, modulation of UCP2 and UCP3 activity
may protect from insulin resistance in addition to
obesity.
Finally, although SLC25A8 and SLC25A9 polymor-
phism may be associated with obesity, diabetes, or
related phenotypes, their impact on these phenotypes
seems to be modest with large heterogeneity between
studies (Dalgaard and Pedersen, 2001). To date, the
effects of UCP2 and UCP3 modulation remain elusive
because human and mouse data did not clearly demon-
strate whether the transporters should be activated or
inhibited for therapeutic intervention. The functional
characterization based on human association stud-
ies and on mouse models is very complex and needs
further evaluation. Nevertheless, the link betweenUCP
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function and dysfunction and metabolic disease is well
established and supports the idea of targeting UCPs.
3. Solute Carrier 25A13/Aspartate–Glutamate Car-
rier 2.
a. Mitochondrial aspartate–glutamate transport.
The aspartate–glutamate carrier 2 (AGC2), also known
as citrin, adult-onset citrullinemia type II (CTLN2), or
aralar2, is encoded by the SLC25A13 gene and facili-
tates the calcium-dependent exchange of cytoplasmic
glutamate with mitochondrial aspartate across the
inner mitochondrial membrane (Fig. 1). AGC2 is a key
component of the malate–aspartate shuttle and essen-
tial to export aspartate from the mitochondrial matrix
to the cytosol. Aspartate is required for urea synthesis
from ammonia and alanine, protein synthesis, gluco-
neogenesis from lactate, as well as the oxidation of
cytosolic NADH (Palmieri, 2004). The transporter is the
only aspartate–glutamate carrier isoform expressed in
the liver (Fig. 2). Hence, in the liver, mutations in the
SLC25A13 gene cannot be compensated by another
transporter system and can cause two age-dependent
autosomal–recessive diseases: neonatal intrahepatic
cholestasis by citrin deficiency (NICCD) and CTLN2,
an accumulation of ammonia and other toxic substances
in the blood.
b. Solute carrier 25A13 genetic variants.
Mutated SLC25A13 has been identified in patients
suffering from type II citrullinemia and proposed to
affect urea cycle function (Kobayashi et al., 1999). In
2001, two reports linked SLC25A13mutations to a neo-
natal liver disease (Ohura et al., 2001; Tazawa et al.,
2001). Multiple case reports with over 50 different
SLC25A13 gene mutations further underpin AGC2
dysfunction in human metabolic disease (Table 1).
Hepatocytes have limited capacity to take up extracel-
lular aspartate. Therefore, both AGC2-related disease
phenotypes are mainly caused by reduced cytosolic
aspartate and hepatic NADH reoxidation (Palmieri
and Monne, 2016). AGC2 deficiency decreases hepatic
argininosuccinate synthetase activity, causing hyper-
ammonemia and citrullinemia. Additionally, reduced
malate–aspartate shuttle activity increases the cyto-
solic NADH/NAD1 ratio, resulting in the inhibition of
glycolysis and alcohol metabolism. The mechanisms
explain carbohydrate and alcohol intolerance in affected
patients, which exacerbates symptoms, and preference
for high-protein diets containing aspartate. High-
carbohydrate diets increase hepatic triglycerides in
some patients, likely due to compensatory malate–
citrate shuttling transferring reducing equivalents
to the mitochondria, thereby producing acetyl-CoA
in the cytosol and stimulating fatty acid synthesis
(Palmieri, 2004).
Neonatal NICCD is characterized by transient intra-
hepatic cholestasis, fatty liver, hepatomegaly, ketotic
hypoglycemia, hypoproteinemia, and aminoacidemia.
Due to liver dysfunction, some patients experience
hepatitis, jaundice, decreased coagulation factors, he-
molytic anemia, and bleeding diathesis. NICCD is
usually benign, and symptoms disappear after a few
years. In adulthood, some patients develop CTLN2,
which is associated with hypoproteinemia and hyper-
ammonemia, leading to a neurological manifestation,
including encephalopathy and neuropsychiatric symp-
toms (Palmieri, 2004, 2013; Palmieri andMonne, 2016).
Some adult patients also manifest fatty liver and
hyperlipidemia unrelated to obesity or ethanol con-
sumption, pointing to the essential function of the
aspartate–glutamate transporter in hepatic metabo-
lism. Finally, SLC25A13 mutations have been linked
to steatosis, nonalcoholic steatohepatitis, and hepato-
cellular carcinoma (Takagi et al., 2006; Tsai et al., 2006;
Fukumoto et al., 2008; Komatsu et al., 2008; Chang
et al., 2011). For patients with CTLN2, liver trans-
plantation is one of the most promising prospects.
However, dietary supplementation can ameliorate
symptoms; patients with NICCD usually respond to
medium-chain triglyceride supplements and lactose-
restricted formulas, whereas medium-chain triglycer-
ide supplements with low-carbohydrate formulas are
recommended for CTLN2 (Hayasaka et al., 2012, 2014,
2018; Hayasaka and Numakura, 2018).
c. Metabolic phenotype of animal models.
Beneficial responses to dietary interventions have also
been shown in Slc25a13 knockout mice, indicated
through increased food intake and maintained body
weight following supplementation with protein or
medium-chain triglycerides (Saheki et al., 2012). Ini-
tially, the Slc25a13 knockout mouse model failed to
mimic CTLN2 and did not show changes in glucose,
amino acid, or ammonia metabolism. At least in mice,
AGC2 deficiency may not be sufficient to elicit liver
disease (Sinasac et al., 2004). Because enhanced glyc-
erol phosphate shuttle activitymay be compensating for
the loss of AGC2 function, Slc25a13 Gpd2 (glycerol
3-phosphate dehydrogenase 2) double-knockout mice
were generated. The model developed citrullinemia,
hyperammonemia, hypoglycemia, and a fatty liver,
displaying features of human AGC2 deficiency (Saheki
et al., 2007).
Taken together, the phenotypes of AGC2 deficiency
have been extensively investigated in human beings
and in mice (Saheki and Song, 2005; Hayasaka and
Numakura, 2018). However, AGC2 was never sug-
gested as target to treat fatty liver, possibly because
dietary interventions and liver transplantation are well
established treatments for NICCD and CTLN2. More-
over, pharmacological activation of the transporter
seems to be challenging. AGC2 deficiency associated
with fatty liver is only one symptomatic feature inhumans
and has never been directly related to obesity ormetabolic
disease. Given the complex physiological function of the
hepatic aspartate–glutamate carrier, additional research
on the role of AGC2 in obesity-related metabolic disease
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may be worthwhile and could generate novel thera-
peutic concepts beyond the two well-known human
phenotypes.
4. Solute Carrier 25A20/Carnitine–Acylcarnitine
Carrier.
a. Mitochondrial carnitine–acylcarnitine transport.
The broadly expressed mitochondrial carnitine–
acylcarnitine carrier (CAC), product of the SLC25A20
gene, catalyzes the exchange between cytosolic acylcarni-
tine that enters themitochondria and intramitochondrial-
free carnitine that is transferred into the cytosol (Figs. 1
and 2). Thereby, CAC is a key component of the
carnitine shuttle system. The system transfers acyl
groups from acyl-CoA to carnitine by the outer mito-
chondrial membrane carnitine palmitoyltransferase 1,
translocates acylcarnitines across the inner mitochon-
drial membrane by CAC, and finally transfers the acyl
groups from acylcarnitines to CoA inside mitochondria
by carnitine palmitoyltransferase 2. The mechanism
imports acyl groups of cytosolic long-chain fatty acids
into mitochondria. In mitochondria, acyl groups are
oxidized by the b-oxidation pathway, the major energy
source for heart and skeletal muscle during periods of
fasting and physical exercise (Indiveri et al., 2011;
Palmieri, 2013). As this pathway is fundamental in
cellular energy metabolism, CAC transporter dysfunc-
tion leads to a severe disease known as CAC deficiency
(Table 1).
b. Solute carrier 25A20 genetic variants. CAC
deficiency was described in 1992 as an autosomal
recessive disorder (Stanley et al., 1992). The first
pathogenic SLC25A20 gene mutation was reported in
1997 (Huizing et al., 1997). Over 40 additional muta-
tions have since been described as resulting in the
complex disease pattern that clinically manifests with
episodes of coma upon fasting, cardiomyopathy, hypo-
tonia, muscle weakness, respiratory distress, seizures,
and hepatic dysfunction (Indiveri et al., 2011; Palmieri
and Monne, 2016). Multiple circulating metabolites are
abnormal in this condition. Key findings include hypo-
glycemia secondary to oxidation of glucose instead of
ketone bodies in the muscle during fasting, as well as
hypoketosis, hyperammonemia, dicarboxylic aciduria,
and increased levels of transaminases and long-chain
acylcarnitines. The clinical symptoms are well charac-
terized and based on the energy deficit in tissues that
rely on fatty acid oxidation. Moreover, elevated acylcar-
nitine levelsmay damage the heart and skeletalmuscle,
whereas hypoketosis, hyperammonemia, and hypogly-
cemia result in the neurological phenotype (Indiveri
et al., 2011; Palmieri, 2013). The disease can occur in
amild or severe form, with remaining protein activity of
about 5% or below 1%, respectively. CAC pathophysiol-
ogy, common clinical features, and interventions of the
disease have been reviewed recently (Indiveri et al.,
2011; Yan et al., 2017). The severe phenotype is usually
present in the neonatal period with a high mortality
rate within the first year of life due to cardiac arrest and
respiratory failure (Yan et al., 2017). Therefore, early
appropriate diagnosis and treatment are necessary to
manage the highly lethal disorder and to ameliorate
disease progression. Therapeutic approaches include
intravenous glucose injection to suppress fatty acid
mobilization and oxidation, as well as ammonia de-
toxification through arginine administration. Long-
term management requires strict diet with frequent
meals to avoid fasting periods, high-carbohydrate in-
take, medium-chain triglyceride supplementation, and
limitation of long-chain fatty acids (Indiveri et al., 2011;
Yan et al., 2017).
In summary, given the severity of CAC deficiency and
the limited success of existing therapies, research on
new therapeutic approaches is needed. Moreover,
whether direct CAC modulation could ameliorate other
disorders, including obesity-related metabolic disease,
deserves to be studied. However, more common genetic
polymorphisms may not result in a dramatic loss of
protein activity and have not been associated with other
disease phenotypes. Slc25a20 knockout mice are not
available to test its obesity-related phenotype under
HFD feeding. Keeping in mind the crucial function of
the transporter in energy metabolism and the severe
metabolic defects in CAC deficiency, research in this
direction should be considered.
5. Solute Carrier 25A24/ATP-Mg/Phosphate Carrier
Protein 1.
a. Mitochondrial transport of adenine nucleotides.
The mitochondrial ATP-Mg/phosphate carrier protein
(APC)1, encoded by SLC25A24, is broadly expressed
and facilitates exchange of adenine nucleotides, including
ATP-Mg, ATP, ADP, and AMP, and phosphate between
mitochondrial matrix and cytosol (Figs. 1 and 2). The
transporter regulates adenine nucleotide concentrations
in the mitochondrial matrix, thereby affecting mito-
chondrial adenine-nucleotide–dependent enzymes, which
regulate gluconeogenesis from lactate, urea synthesis,
mitochondrial DNA replication, transcription, and pro-
tein synthesis, among others (Palmieri andMonne, 2016).
b. Solute carrier 25A24 genetic variants. SLC25A24
was proposed as a novel susceptibility gene for low fat
mass in humans (Urano et al., 2015) (Table 1). Using
SNP arrays, three SNPs in the SLC25A24 gene were
associated with body fat percentage and BMI
(rs491785, rs519129, and rs547364) in Japanese post-
menopausal women (Urano et al., 2015). Subjects
harboring the major alleles had lower body fat per-
centage and BMI and the rs491785 major allele
associated with lower SLC25A24 mRNA expression
in human preadipocytes. No additional gene variants
linked to disease phenotypes in other populations and/
or larger study cohorts are known.
c. Metabolic phenotype of animal models.
Slc25a24 knockout mice are resistant to HFD-induced
obesity with significantly reduced white adipose tissue
SLC Transporters as Targets to Treat Metabolic Disease 363
and liver weights (Urano et al., 2015). The phenotype
was linked to reduced adipocyte differentiation marker
expression and reduced hepatic triglycerides in Slc25a24
knockout mice (Urano et al., 2015).
In conclusion, APC1 may be linked to obesity in
humans and mice. Further studies are needed to verify
these data and clarify APC1-regulatedmechanisms and
(patho)physiology in more detail.
6. Therapeutic Potential of Solute Carrier 25
Transporters. Summarizing the SLC25 family of mi-
tochondrial carriers (Table 1), SLC25A7/UCP1 seems to
be the most promising candidate to target for the
treatment of obesity and related metabolic diseases.
Although SLC25A8/UCP2 and SLC25A9/UCP3 are
linked to obesity, diabetes, or related phenotypes,
studies are heterogeneous and partially controversial.
Nevertheless, the link between UCP function and
dysfunction and metabolic disease is well established,
especially for UCP1, and the obvious therapeutic po-
tential should be pursued. In addition to these potential
targets presented in this section, two additional trans-
porters, SLC25A25/APC3, which was linked to resis-
tance to diet-induced obesity in a mouse model,
and SLC25A40/mitochondrial carrier family protein
(MCFP), which was associated with hypertriglyceride-
mia in one human study (Table 2), are discussed in
Emerging Potential of Other Solute Carrier Target
Structures.
D. Solute Carrier 30: The Zinc Transporter Family
Zinc is crucial for the function of numerous enzymes
and proteins that participate in the metabolism of
proteins, nucleic acids, carbohydrates, and lipids
(Vallee and Falchuk, 1993). It affects various biological
processes, including growth, development, and neuro-
nal and immune function, and its cellular homeostasis
needs to be tightly controlled as both zinc deficiency and
excess are toxic to cells (Sekler et al., 2007). Zinc levels
are regulated by metalloproteins and two different
families of zinc transporters with opposite functions:
SLC30 and SLC39. Transporters of the SLC30 family
[zinc transporter (ZnT)] mediate efflux from the cytosol
into cytosolic compartments or the extracellular space
when cytosolic zinc concentration is high. Transporters
of the SLC39 family (zinc–iron permease) mediate zinc
influx into the cytoplasm in the face of low cellular
concentration (Palmiter and Huang, 2004). Although
ZnT1 (SLC30A1) primarily functions as plasma
membrane efflux transporter, other family members
are mainly localized in intracellular membranes.
The SLC30 family consists of 10 members that are
expressed at the plasma membrane to transport cyto-
plasmic zinc out of the cell, thereby preventing zinc
toxicity, or at intracellular membranes to shuttle
cytoplasmic zinc into cellular compartments for secre-
tion, storage, or supply for zinc-containing proteins
(Palmiter and Huang, 2004; Huang and Tepaamorndech,
2013). The detrimental effects of altered zinc transporter
activity and dysregulation of intra- and extracellular
zinc concentrations are illustrated by genetic studies in
humans and in mice. Pathology resulting from altered
SLC39 transporter function includes abnormal embryonic
and immune cell development. In contrast, SLC30
proteins are associated with diabetes, Alzheimer’s, or
Parkinson disease (Hara et al., 2017).
1. Solute Carrier 30A8/Zinc Transporter 8.
a. Zinc and insulin biosynthesis. The most prom-
inent member of the SLC30 family in terms of metabolic
disease is ZnT8, product of the SLC30A8 gene. The
transporter is mainly expressed in the membrane
of insulin secretory granules in pancreatic b-cells
(Figs. 1 and 2) and provides zinc for insulin synthesis
(Chimienti et al., 2004). Zinc concentrations are partic-
ularly high in b-cells, especially in insulin secretory
granules, where it forms crystalloid-like hexamers with
insulin. The process maintains insulin maturation,
storage, and stability (Emdin et al., 1980; Hutton,
1989; Foster et al., 1993; Dodson and Steiner, 1998).
The critical role of zinc in insulin biosynthesis was first
proclaimed when Scott and Fisher (1938) observed
concomitant reductions in insulin and zinc in the
pancreas, but unaltered zinc concentrations in the
livers of patients with diabetes. Serum zinc concentra-
tions are also significantly reduced in patients with
diabetes (Garg et al., 1994). The complex relationship
between zinc and both type 1 and type 2 diabetes has
further been established (Chausmer, 1998;Maret, 2017;
Fukunaka and Fujitani, 2018). Zinc deficiency in
patients with diabetes led to the idea of zinc supple-
mentation to promote b-cell function. The intervention
showed beneficial metabolic effects in humans and
in T2D animal models (Taylor, 2005; Jayawardena
et al., 2012).
b. Solute carrier 30A8 genetic variants. Whether
zinc deficiency in patients with diabetes is the cause or
consequence of the disease was not clear for a long time.
However, a potentially causal relationship was discov-
ered with the identification of a SLC30A8 sequence
variant that increased T2D susceptibility in various
populations worldwide (Table 1). Furthermore, the
transporter was identified as a major autoantigen in
human type 1 diabetes (Wenzlau et al., 2007). The link
to T2D arose with the identification of the SLC30A8
SNP rs13266634 as risk loci for T2D in three indepen-
dent GWAS (Saxena et al., 2007; Scott et al., 2007;
Sladek et al., 2007). The first study analyzed poly-
morphisms in French T2D patients and identified four
novel loci, including SLC30A8. Two additional studies
in Finnish and Swedish subjects described the same
SLC30A8 sequence variant (Saxena et al., 2007; Scott
et al., 2007). The rs13266634 polymorphism leads to
a single base change from C to T with consequent amino
acid change from arginine (R) to tryptophan (W) at
position 325 (c.973C.T; p.R325W). Increased T2D risk
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was associated with the major C-allele and accordingly
the R325 protein variant. The polymorphism is common
in individuals of European and East Asian descents and
associated with a 14% increase in diabetes incidence per
risk allele (Cauchi et al., 2010). The first functional
studies demonstrated that the R325 risk variant is less
active than the low-risk W325 variant (Nicolson et al.,
2009; Kim et al., 2011) and provided evidence that ZnT8
activation could minimize diabetes risk. In fact,
SLC30A8 overexpression in insulinoma cells enhanced
insulin secretion during hyperglycemia. Thus, ZnT8
may promote zinc storage in insulin granules and
thereby the insulin secretory pathway (Chimienti
et al., 2006; Sladek et al., 2007). The ability to transport
and store zinc rather than the extracellular zinc status
is important for zinc accumulation in b-cells. There-
fore, SLC30A8 overexpression could counteract zinc
depletion in diabetes, which likely participates in
b-cell mass loss (Chimienti et al., 2006). According
to the effect of SLC30A8 overexpression on insu-
lin secretion, subjects homozygous for the C-risk
allele exhibit a decrease in first-phase insulin release
after intravenous glucose administration (Boesgaard
et al., 2008).
Influences of endogenous plasma zinc and dietary
zinc supplementation on insulin secretion or T2D risk
have been related to SLC30A8 sequence variants.
Glucose-stimulated insulin secretion in healthy non-
diabetic Amish individuals with and without the
rs13266634 polymorphism was tested before and after
zinc supplementation. Contrary to the previous hypoth-
esis, individuals with the lower-risk CT/TT genotypes
showed attenuated insulin responses to glucose stimu-
lation compared with homozygous C-risk allele carriers
without zinc supplementation (Maruthur et al., 2015).
However, after 14 days of zinc supplementation, the
increase in insulin response to glucose was not signif-
icantly changed in the homozygous risk allele carriers
compared with baseline and was increased further in
the nonrisk CT/TT-allele carriers (Maruthur et al.,
2015). A prospective study of a Swedish cohort presents
zinc supplementation as lowering the risk of T2D, but
does not find significant modification of the zinc–T2D
associations by the SLC30A8 rs13266634 polymor-
phism (Drake et al., 2017). However, T2D risk was
lowest among nonrisk allele carriers on zinc supple-
ments. A Chinese population presented the inverse
association between plasma zinc levels and diabetes.
The association was more pronounced among individu-
als carrying the TT genotype of SLC30A8 rs13266634
polymorphism than those carrying CT or CC genotypes
(Shan et al., 2014). The attenuated inverse association
of zinc level and T2D risk in the subjects carrying the
C-risk allele supports the data sets on zinc supplemen-
tation (Maruthur et al., 2015; Drake et al., 2017).
Apparently, beneficial zinc effects on metabolism are
attenuated in risk allele carriers.
Although the first functional studies of the SLC30A8
risk allele discovered in 2007 predicted reduced trans-
porter activity, SLC30A8 sequence variants lowering
diabetes risk were described in 2014 (Flannick et al.,
2014). Twelve novel SLC30A8 sequence variants,
resulting in a truncated protein and loss of transporter
activity, predicted reduced T2D risk. This publication
was groundbreaking because previous functional stud-
ies of ZnT8 suggested that reduced zinc transport
increases T2D risk, whereas SLC30A8 loss-of-function
mutations provide strong evidence that haploinsuffi-
ciency protects against T2D, and ZnT8 inhibition may
be suitable to treat T2D. However, the novel identified
variants are rare.
c. Metabolic phenotype of animal models. The po-
tential causal role of ZnT8 in T2D has been extensively
investigated in mouse models (Table 1). HFD-fed
Slc30a8 knockout mice are glucose intolerant and
diabetic with less responsive b-cells (Lemaire et al.,
2009). Similarly, chow-fed Slc30a8 knockout mice
showed reduced glucose-stimulated insulin secretion
and lower zinc content of secretory granules, but an
overall mild metabolic phenotype (Nicolson et al., 2009;
Pound et al., 2009). Because ZnT8 is not only expressed
in b-cells, but also in pancreatic a-cells (Nicolson et al.,
2009), the role of ZnT8 in the two different islet
cell populations was further addressed using a b-
cell–specific Slc30a8 knockout mouse. HFD-fed whole-
body Slc30a8 knockout mice became remarkably obese,
hyperglycemic, hyperinsulinemic, insulin resistant, and
glucose intolerant, whereas mice with specific Slc30a8
deletion in b-cells showed an attenuated metabolic
phenotype with a similar body weight to control mice
(Hardy et al., 2012). These data suggest that ZnT8
contributes to the risk of developing T2D through
b-cell– and non-b-cell–specific effects (Hardy et al.,
2012). Indeed, the metabolic function of ZnT8 and
interacting environmental factors, genetic background,
gender, and age ultimately determine the variable
metabolic phenotype of whole-body Slc30a8 knockout
(Lemaire et al., 2009; Nicolson et al., 2009; Pound et al.,
2009, 2012) and b-cell–specific Slc30a8 knockout mod-
els (Wijesekara et al., 2010; Hardy et al., 2012; Tamaki
et al., 2013; Mitchell et al., 2016). However, most of the
studies display abnormalities in insulin crystallization
and storage, impaired glucose tolerance, and lower
circulating insulin levels. Thus, reduced ZnT8 activity
alters glucose homeostasis, thereby increasing T2D risk
(da Silva Xavier et al., 2013). Vice versa, Slc30a8
transgenic mice overexpressing the transporter in
b-cells show markedly improved glucose tolerance
(Mitchell et al., 2016).
Unexpectedly, some studies showed unaltered or
improved insulin release after glucose stimulation of
isolated Slc30a8 knockout b-cells (Lemaire et al., 2009;
Nicolson et al., 2009; Tamaki et al., 2013; Mitchell et al.,
2016). The contradictory observation of lower plasma
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insulin levels in vivo, but improved insulin secretion
in vitro, could be explained by a functional link between
Slc30a8 deletion in b-cells and hepatic insulin clearance
(Tamaki et al., 2013). Zinc secreted along with insulin
from pancreatic secretory granules could conceivably
affect neighboring endocrine cells and the liver. By
inhibiting clathrin-dependent insulin endocytosis, zinc
suppresses hepatic insulin clearance. Insulin uptake in
hepatocytes increases as a result of the lower pancreatic
zinc release in Slc30a8 knockout mice. Indeed, the
study also showed low circulating insulin levels in the
face of insulin hypersecretion from pancreatic b-cells.
Because ZnT8 affects hepatic insulin clearance, genetic
dysregulation of this could contribute to T2D.
HFD-fed transgenic mice overexpressing the human
SLC30A8 high-risk R325 variant exhibit increased
pancreatic zinc and proinsulin levels and decreased
insulin and glucose tolerance, confirming the detrimen-
tal effect of the human risk allele (Li et al., 2017a).
Conversely, overexpression of the low-risk W325 vari-
ant decreases pancreatic zinc and proinsulin levels
together with increases in insulin and glucose tolerance.
The beneficial metabolic response to SLC30A8 over-
expression strongly suggests that ZnT8 activation could
ameliorate metabolic disease. This idea is further
supported by the fact that pancreatic ZnT8 protein
levels are downregulated in diabetic disease models
such as db/db and Akita mice in the early stages of T2D
(Tamaki et al., 2009).
In contrast to previously describedmouse phenotypes
and gene expression data stressing potential benefits of
ZnT8 activation, a recent study of knockinmice carrying
a human SLC30A8 loss-of-function variant yielded
unexpected findings. The model featured increased
glucose-induced insulin secretion, likely reflecting in-
creased capacity of b-cells to secrete insulin. The study
suggested for the first time that ZnT8 inhibition could
elicit beneficial metabolic responses (Kleiner et al.,
2018), supporting the finding of SLC30A8 loss-of-
function variants that reduced T2D risk (Flannick
et al., 2014). Although loss of function seems to be
beneficial in this mouse line, the variability of mouse
phenotypes makes it difficult to judge how ZnT8 must
be modulated to achieve metabolic protection.
d. Pharmacological activation or inhibition of zinc
transporter 8. The diabetic phenotypes of the knock-
outmice and human data onSLC30A8 genetics and zinc
supplementation support the idea that ZnT8 aug-
mentation could improve T2D. However, discrepant
data concerning the metabolic effect of the risk allele
raise the question of whether the SLC30A8 risk variant
causes an increase or a decrease in zinc transport
activity. Accordingly, whether ZnT8 activation or in-
hibition should be pursued as T2D treatment remains
unclear. Whereas in mice loss of ZnT8 function results
in impaired glucose tolerance, human data are contra-
dictory, with studies describing high-risk and low-risk
variants with loss of function. The SLC30A8 R325 risk
variant displayed lower zinc transport (Nicolson et al.,
2009), but was proposed to be hyperactive in another
study (Merriman et al., 2016) that is supported by
the finding that the diabetes risk genotype CC at
rs13266634 is associated with higher islet zinc concen-
trations (Wong et al., 2017), along with the identification
of rare T2D-risk–reducing SLC30A8 loss-of-function
mutations (Flannick et al., 2014). The following concept
may explain the paradoxical finding that high-risk and
low-risk variants both present lower protein activity
(Rutter and Chimienti, 2015): assuming the activity of
the risk variant is 30% lower compared with the
nonrisk variant, zinc transport into granules would
be reduced by 15% and 30% in heterozygous and
homozygous C-allele carriers. In contrast, heterozy-
gous loss-of-function variants result in 50% lower
activity. Consequently, the rare loss-of-function muta-
tions result in a lower transport activity compared
with the rs13266634 risk variant. The risk variant
R325 results in moderate reduction of ZnT8 activity,
lowering b-cell zinc secretion and enhancing hepatic
insulin clearance. In contrast, more severe reduction in
ZnT8 function increases insulin secretion from b-cells,
compensating the impaired zinc release and insulin
clearance. This model argues for a complex dose–
response relationship between ZnT8 activity and
diabetes risk (Rutter and Chimienti, 2015). Species-
specific differences may explain the increased risk of
hyperglycemia in Slc30a8 knockout mice with the
simpler model of progressively impaired insulin action
due to increased hepatic clearance. Moreover, the
differential role of ZnT8 in insulin secretion and
glucose homeostasis could be explained in part by an
age-dependent effect (Rutter and Chimienti, 2015).
This idea originated from the observation of impaired
glucose tolerance and abnormal insulin granules in
younger (6–8 weeks old), but not in older Slc30a8
knockout mice (Nicolson et al., 2009). Furthermore,
pancreatic islet cell survival in the face of hypoxia was
enhanced in older (.12 weeks) Slc30a8 knockout mice,
but not younger animals (Gerber et al., 2014). How-
ever, whether findings in rodents can be translated to
human disease remains unclear, and particularly the
interaction with age, gender, drugs, or physical activ-
ity may influence ZnT8 function.
Taken together, both rodent and humandatahighlight
the significance of ZnT8 function in glucose homeostasis
and the pathological consequences of ZnT8 malfunction.
However, drug interventions targeting ZnT8 are likely
complex given the proposed bell-shaped model of the of
ZnT8 function in the development of T2D. Clearly, effects
of both activating and inhibiting drugs will need to be
investigated in suitable models prior to clinical trials in
human beings (Rutter and Chimienti, 2015).
2. Therapeutic Potential of Solute Carrier 30
Transporters. Because zinc transporters are crucial
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for zinc homeostasis, any dysregulation could promote
development of metabolic disease, particularly diabe-
tes mellitus. Regarding existing data on the SLC30
family of zinc transporters, SLC30A3/ZnT3 is linked to
insulin secretion and SLC30A7/ZnT7 shows an associ-
ation with diet-induced obesity and insulin resistance
in mice (Table 2). Both SLC30 members will be
discussed in Emerging Potential of Other Solute
Carrier Target Structures. Finally, SLC30A8 is the
only candidate gene that has been linked to human
T2D in genetic studies and is therefore the most
promising target for a therapeutic intervention
(Table 1). Research on ZnT8 is ongoing; since 2018,
multiple studies regarding T2D susceptibility in dif-
ferent populations have been published, highlighting
the critical role of this zinc transporter in the onset
of human diseases (Ding et al., 2018; Dong et al., 2018;
Li et al., 2018; Lin et al., 2018; Liu et al., 2018;
Plengvidhya et al., 2018). Further studies are needed
to finally verify whether increased or decreased trans-
porter activity is linked to human T2D, and therefore
whether inhibition or rather activation of the trans-
porter is required to counteract disease development.
However, ZnT8 seems to be a promising therapeutic
target for the treatment of T2D and potentially also
related metabolic diseases, and should therefore be
investigated further.
IV. Proposed Requirements for Metabolic
Target Structures
In this review, we evaluate metabolic target struc-
tures by the available data supporting their role in
metabolic regulation and exploitability in human met-
abolic disease (Tables 1 and 2). A protein may be
regarded as a potential target if its genetic locus and
protein function in the setting of metabolic disease are
established in cellular systems, animal models, and
human beings. Cell-based studies can point to effects of
specific targets on insulin secretion [e.g., ZnT3 (Smidt
et al., 2009)], glucose uptake [e.g., SGLT1 and SGLT2
(Ghezzi et al., 2018)], or oxygen consumption [UCP1
(Ost et al., 2017)]. Ideally, an animal model then
substantiates the effect by showing relevance in a dis-
ease model of genetic and diet-induced obesity, insulin
resistance, NAFLD, and b-cell loss. Metabolic effects of
transporter modulation should be investigated in ani-
mal models such as the obese insulin-resistant ob/ob or
diabetic db/db mice, or knockout mice. However, the
classification of a metabolic target also requires human
validation because it has become clear that a large part
of the available animal data does not translate into the
human setting (Perel et al., 2007; Mak et al., 2014).
Ideally, either GWA or MR studies should validate and
substantiate experimental data from cells and animals.
However, functionally relevant polymorphisms may be
too rare, and the number of patients needed to show
conclusive, statistically significant results in GWAS or
MR, after adjusting for multiple testing, may exceed the
size of existing cohorts. Therefore, studies using human
specimens, disease-related regulation of gene expres-
sion, or functional changes in the setting of metabolic
disease may complement the picture consisting of
cellular, systemic animal and human data.
A prime example for our proposed requirements is the
SLC5 family member SGLT2, which fulfilled all defined
criteria and is to date one of the preferred targets with
which to treat T2D: 1) SGLT2 has been shown to
mediate glucose uptake in cellular systems (Ghezzi and
Wright, 2012); 2) animal models lacking SGLT2 were
protected fromdiet-induced and genetic obesity, T2D, and
b-cell loss (Jurczak et al., 2011, 2018); and 3)mutations in
humans provided evidence for a clear role of SGLT2 in
renal glucose handling (Santer et al., 2000, 2003; van den
Heuvel et al., 2002). Finally, the SGLT2 inhibitor phlor-
izinwas available andwas proven beneficial in the setting
of diabetes in animals (Ehrenkranz et al., 2005). To-
gether, these data resulted in the development of clini-
cally available SGLT2 inhibitors for the treatment of T2D,
which have not only shown their potency and efficacy in
reducing glycemia, but also in mediating cardiovascular
benefit such as reduction in heart failure hospitalization
and progression of kidney disease in patients with and
without pre-established cardiovascular disease (Hanefeld
et al., 2016; Birkenfeld et al., 2019; Zelniker et al., 2019).
V. Emerging Potential of Other Solute Carrier
Target Structures
This review aims to elucidate members of the SLC
superfamily that are linked to humanmetabolic disease
and could serve as treatment targets. The potential and
relevance of the transporters in metabolic function and
dysfunction were gauged based on existing human
and mouse data. Some associations of transporter-
encoding SLC gene variants are very strong and are
underpinned by GWAS or other genome analyses, as
well as by phenotype-related mouse models. Transport-
ers that show a clear link in human metabolic disease or
at least some link combined with strong supporting
mouse datawere presented inLinks toHumanMetabolic
Disease and Potential Targets and Table 1. Other SLC
genes of the selected families are linked to metabolic
disorders only in rodent models or are only marginally
linked to metabolic disease in humans. The SLC mem-
bers presented in this section include those with the
potential for future research; however, existing data are
not to date sufficiently conclusive to propose the trans-
porter as a target to treatmetabolic disease. An overview
of these SLC members is presented in Table 2.
A. Solute Carrier 5 Family
SLC5A1/SGLT1 and SLC5A2/SGLT2 are the most
prominent members of the SLC5 family given their
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close association with metabolic disease (Table 1) and
drugs targeting the transporters showing benefits in
multiple clinical trials. However, other SLC5 family
members may have potential in the management of
metabolic disease. These candidates, such as SLC5A9/
SGLT4 and SLC5A10/SGLT5, are linked to diabetic
retinopathy and hepatic steatosis (Table 2).
1. Solute Carrier 5A9/Sodium–Glucose Cotrans-
porter 4. SGLT4, encoded by the SLCA9 gene, is
a transporter for mannose, glucose, and fructose pri-
marily expressed in the intestine, but also in the kidney
and liver (Tazawa et al., 2005). SGLT4 likely contrib-
utes to intestinal absorption and renal reabsorption
of sugar analogs, including mannose, but also 1,5-
anhydro-D-glucitol. Elevated mannose serum concen-
trations are associated with diabetes mellitus and the
metabolic syndrome (Pitkänen, 1996; Pitkänen et al.,
1999). Conversely, 1,5-anhydro-D-glucitol serum con-
centrations are reduced in diabetic patients (Servo and
Pitkänen, 1975; Akanuma et al., 1981; Yamanouchi
et al., 1991; Pitkänen, 1996). The SLC5A9 gene muta-
tions may contribute to changes in serum metabolites
seen in diabetic patients (Tazawa et al., 2005). A recent
study suggested an association between three rare
SLC5A9 variants—rs149485404, rs775853981, and
rs61997217—and proliferative diabetic retinopathy
(Ung et al., 2017), which is a common complication of
diabetes and a leading cause of blindness worldwide.
However, the study cohort only comprised a limited
number of patients. Taken together, human data are
scarce, and, until now, SLC5A9 variants or mutations
have not directly been linked to diabetes and metabolic
syndrome. A Slc5a9-deficient mouse model could prove
the hypothesis of physiological implications in T2D and
related clinical complications.
2. Solute Carrier 5A10/Sodium–Glucose Cotrans-
porter 5. SGLT5, product of the SLC5A10 gene, is
exclusively expressed in the kidney and transports
mannose and fructose with high capacity and to a lesser
extent glucose and galactose (Grempler et al., 2012).
Physiologically, SGLT5mediates the reabsorption of its
substrates from urine into renal proximal tubule cells.
The SLC5A10 variant rs117355297 and two rare loss-
of-function mutations are significantly associated with
circulating 1,5-anhydro-D-glucitol (Li et al., 2017b;
Long et al., 2017), an accepted biomarker heralding
diabetic complications (Parrinello and Selvin, 2014).
Slc5a10 knockout mice showed increased urinary
fructose, indicating that SGLT5 is important for renal
fructose reabsorption (Fukuzawa et al., 2013). Because
high fructose intake is epidemiologically associated
with dyslipidemia, obesity, NAFLD, diabetes, and
cardiovascular disease (Johnson et al., 2007; Stanhope
andHavel, 2010), the authors hypothesized that SGLT5
deficiency could protect from fructose-induced hepatic
steatosis. Surprisingly, SGLT5deficiencyworsened fructose-
induced hepatic steatosis, plasma transaminases, and
fasting hyperinsulinemia in another study (Fukuzawa
et al., 2013). To date, the transporter has not been
related to human disease, but mouse data, although
conflictive, suggest that the contribution of SGLT5 in
fatty liver disease deserves to be studied in more detail.
B. Solute Carrier 13 Family
Three additional SLC13 transporters might have
potential besides the promising candidate SLC13A5/
NaCT (Tables 1 and 2). SLC13A2/NaDC1 and
SLC13A3/NaDC3 are associated with renal function
and disease in GWAS and could be further investi-
gated as potential targets to treat diabetic nephrop-
athy or other kidney diseases. Moreover, SLC13A1/
NaS1 has been linked to fatty liver disease in a well-
described knockout mouse model. However, their poten-
tial in the context of obesity or T2D has not been
sufficiently examined.
1. Solute Carrier 13A1/Sodium-Coupled Sulfate
Cotransporter 1. NaS1, product of the SLC13A1 gene,
mediates the absorption of sulfate, an essential micro-
nutrient required for various physiological processes, in
the small intestine and its reabsorption in the kidney,
thereby regulating sulfate plasma level and sulfate
homeostasis (Markovich, 2001; Markovich and Murer,
2004). The two single-nucleotide variants, rs28364172
and rs138275989, were shown to be strongly associ-
ated with low serum sulfate level, a so-called hyposul-
fatemia, as well as the high serum level of the liver
transaminases alanine aminotransferase and aspartate
aminotransferase (Tise et al., 2016). A potentially
detrimental effect of disturbed sulfate homeostasis on
liver metabolism is supported by the hyposulfatemic
Slc13a1 knockoutmousemodel showing altered hepatic
gene expression associated with increased hepatic lipid,
serum cholesterol, and low-density lipoprotein concen-
tration, as well as reduced hepatic glycogen content
(Dawson et al., 2006). Although human NaS1 is not
convincingly related to metabolic disease patterns,
rodent data support the hypothesis that NaS1 activa-
tion might be metabolically beneficial. However, be-
cause NaS1 interferes with multiple physiological
processes, as evidenced by neurological and behavioral
abnormalities, enhanced tumor growth, and reduced
fertility in Slc13a1 knockout mice (Dawson et al., 2003,
2004, 2005, 2010, 2011), consequences of NaS1 modu-
lation seem complex, and the idea and consequences of
transporter modulation need further investigation.
2. Solute Carrier 13A2/Sodium-Coupled Di- and
Tricarboxylate Transporter 1. NaDC1, encoded by
the SLC13A2 gene, is mainly expressed in the apical
membrane of renal proximal tubular and small in-
testine cells, where it reabsorbs TCA cycle intermedi-
ates such as succinate, a-ketoglutarate, and citrate,
thereby providing substrates for cells with high meta-
bolic needs (Chen et al., 1998). The key physiological
role of the NaDC1 transporter is the regulation of
368 Schumann et al.
urinary citrate excretion. An important function of
citrate in the urine is complexing calcium and thereby
preventing calcium crystallization and precipitation
(Bek-Jensen et al., 1996). Low urinary citrate excretion,
a so-called hypocitraturia, increases the risk of neph-
rolithiasis, the formation of calcium-containing renal
stones (Kleeman et al., 1980; Rudman et al., 1982; Nicar
et al., 1983; Hamm, 1990). Findings in human beings
and rodents relate NaDC1 to nephrolithiasis (Table 2).
Notably, links between nephrolithiasis and metabolic
disease have been extensively discussed. For example,
the hazard ratio for new-onset T2D increased in patients
with renal stones (Chung et al., 2011). Additional stud-
ies highlighting the link between nephrolithiasis and
the metabolic syndrome, cardiovascular disease, hyper-
tension, and diabetes have been recently reviewed
(Ramaswamy and Shah, 2014).
The A-allele of the SLC13A2 polymorphism
rs11567842 (c.1648A.G; p.I550V) is associated with
reduced urinary citrate concentrations (Okamoto et al.,
2007), whereas the G-allele variant is significantly
associated with increased urinary citrate excretion,
suggesting that AA-allele carriers are more susceptible
to hypocitraturia, which increases their risk for renal
stone recurrence (Udomsilp et al., 2018). No significant
association of the polymorphism with presence of renal
stone formation was observed, indicating that the
SNP itself may not be sufficient to affect formation of
kidney stones. In the presence of additional metabolic
risks, however, nephrolithiasis may occur earlier in
A-allele–carrying subjects (Okamoto et al., 2007).
The authors suggest that patients with recurrent
kidney stones carrying the A-allele of the rs11567842
polymorphismmight benefit in terms of nephrolithiasis
risk from citrate-rich diets to increase urinary citrate
excretion.
Slc13a2 knockout mice excreted significantly larger
amounts of TCA cycle intermediates in urine (Ho et al.,
2007), confirming the human data (Okamoto et al.,
2007; Pajor and Sun, 2010; Udomsilp et al., 2018).
However, in this model, renal function was not affected
under normal or ischemic conditions and no additional
metabolic changes were observed. In rats, Slc13a2
expression was increased on renal proximal tubule
epithelial cells in a model of chemically-induced
nephrolithiasis (He et al., 2004b). Nevertheless, re-
nal NaDC1 expression was reduced in a rat model of
obstructive nephropathy, which can be caused by
nephrolithiasis (Campagno et al., 2018). Finally, the
opposing regulation of Slc13a2 in different animal
models needs further evaluation.
NaDC1 has also been hypothetically implicated in the
pathogenesis of arterial hypertension (Bergeron et al.,
2013). The idea is based on the knowledge that the
renal function and blood pressure regulating serum and
glucocorticoid-regulated kinase 1 signaling pathway stim-
ulates NaDC1, and succinate, also a NaDC1 substrate,
increases blood pressure in animals. This effect is
absent in G protein–coupled receptor 91 (succinate
receptor)–deficient mice (Boehmer et al., 2004; He
et al., 2004a; Bergeron et al., 2013). However, a direct
link betweenNaDC1 function and arterial hypertension
has not yet been proven.
Taken together, NaDC1 appears to affect suscep-
tibility to develop nephrolithiasis. Mechanistically,
SLC13A2 polymorphisms in humans with decreased
transporter function and genetic Slc13a2 deletion in
mice both raise urinary citrate levels. Because citrate
attenuates renal stone formation, NaDC1 inhibition
could be therapeutically useful against nephrolithiasis.
Although nephrolithiasis has been linked to diabetes
(Chung et al., 2011; Ramaswamy and Shah, 2014), it
is questionable whether NaDC1 targeting has the
potential to treat metabolic disease. In fact, SLC13A2
polymorphisms have not been directly linked to obesity,
diabetes, insulin resistance, or fatty liver in human
beings. Further investigations, especially in mouse
models of diet-induced obesity, are needed to verify
the potential of NaDC1.
3. Solute Carrier 13A3/Sodium-Coupled Di- and
Tricarboxylate Transporter 3. NaDC3, encoded by the
SLC13A3 gene, is primarily expressed in the kidney,
liver, and brain (Fig. 2) and exhibits substrate specific-
ities similar to those of NaDC1 (Fig. 1) (Chen et al.,
1999). The most physiologically important NaDC3
substrate is a-ketoglutarate. In the kidney and liver,
NaDC3 is expressed on the basolateral membrane
supplying TCA cycle intermediates for mitochondrial
energymetabolism. The substrates may also be used for
gluconeogenesis (Chen et al., 1999). Furthermore, in the
liver, NaDC3 likely plays a role in glutamine and
ammoniametabolism. In the kidney, NaDC3 is involved
in organic anion secretion by taking up a-ketoglutarate
from blood (Bergeron et al., 2013). Importantly, NaDC3
acts in concert with the organic anion transporter OAT2
(SLC22A7), which facilitates the import of organic
anions in exchange for dicarboxylates (Bergeron et al.,
2013). Through this interaction, both transporters
regulate the secretion of organic anions. In the brain,
the transporter is mainly expressed in astrocytes, but
not in neurons. It is supposed that supply with dicar-
boxylates is mediated by NaDC3 in astrocytes and
NaCT in neurons (Bergeron et al., 2013).
The two SLC13A3 SNPs, rs126917 and rs2425885,
have been linked to T2D and end-stage renal disease
(Bento et al., 2008). However, the identified polymor-
phisms are possibly associated with diabetic nephrop-
athy rather than T2D, and therefore, similar to NaDC1,
further studies of patients with diabetes, but without
nephropathy, are needed to clarify disease specificity.
Another GWAS yielded a significant association for
the SLC13A3 polymorphism rs6066043 and chronic
kidney disease of unknown etiology (Nanayakkara et al.,
2014). Indeed, renal Slc13a3 expression was positively
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correlatedwith progressive renal fibrosis inmice aswell
as in kidney biopsies obtained from patients with stage
III/IV chronic kidney disease, suggesting SLC13A3
gene and protein expression as a potential molecular
biomarker for disease progression (Ju et al., 2009).
Besides the presented renal disease patterns, the
SLC13A3 polymorphism rs6066029 was linked to arte-
rial hypertension (Simino et al., 2011). The authors
proposed “suggestive” associations between blood pres-
sure and the rs6066029 variant, defined by a less
stringent genome-wide significance threshold com-
pared with the conventional statistical significance
threshold that is conservative for limited sample size
or rare variants (Simino et al., 2011). Additionally,
NaDC3 may also be involved in the pathogenesis of
inborn metabolic diseases, including glutaric aciduria
type 1, Canavan disease, and Axenfeld–Rieger syn-
drome type 1 (Bergeron et al., 2013).
Taken together, existing human genetic association
data are scarce and inconclusive; strong genotype
phenotype correlation is not shown in larger cohorts.
Nevertheless, several studies have linked NaDC3 to
diabetes, hypertension, and, most importantly, renal
disease (Table 2). Because direct links between NaDC3
and diabetes have not been established, further GWAS
and valid animal models are required to validate
a causative link. It remains to be seen whether NaDC3
could serve as pharmacological target for the treatment
of metabolic disease.
C. Solute Carrier 16 Family
Besides the extensively discussed potential targets
SLC16A1/MCT1, SLC16A11/MCT11, and SLC16A13/
MCT13 (Table 1), additional SLC16 transporter might
be interesting in the context of metabolic disease.
SLC16A3/MCT4 has been linked to diabetic nephrop-
athy, and SLC16A6/MCT7, SLC16A9/MCT9, and
SLC16A10/MCT10 are marginally linked to metabolic
phenotypes in single animal or human studies (Table 2).
1. Solute Carrier 16A3/Monocarboxylate Transporter
4. MCT4, encoded by the SLC16A3 gene highly
expressed in the skeletal muscle, brain, and intestine,
is a well-characterized proton-coupledmonocarboxylate
transporter whose pathophysiology, similarly to MCT1,
has mainly been studied in cancer research (Jones and
Morris, 2016; Fisel et al., 2018). Interestingly,SLC16A3
was linked to diabetic nephropathy, a common compli-
cation of diabetes, in a gene expression study in ethnic
Malays with T2D. SLC16A3 overexpression was de-
scribed in patients with diabetes and renal impairment,
suggesting that SLC16A3 may confer susceptibility
for diabetic nephropathy (Lokman et al., 2011).
SLC16A3 gene expression was also studied in patients
with obesity; SLC16A3 tended to be overexpressed in
patients with obesity before weight loss and slightly
decreased after weight loss (Metz et al., 2008). However,
for both human studies, the number of patients was
limited, and large-scale studies need to confirm the
associations to diabetic nephropathy and obesity. Fur-
ther investigations, including the characterization of
a Slc16a3-deficient mouse line, are needed to evaluate
the real potential of this transporter.
2. Other Solute Carrier 16 Transporters. Other
SLC16 family members are less characterized and only
marginally described in the context of metabolic dis-
ease. MCT7, encoded by the SLC16A6 gene, transports
ketone bodies and is broadly expressed. A Slc16a6
mutation was identified in zebrafish mutants with
hepatic steatosis. The phenotype could be rescued by
transgenic expression of the human ortholog SLC16A6
(Hugo et al., 2012). However, rodent and human data
linking SLC16A6 expression and fatty liver are lacking.
SLC16A9, coding for the carnitine transporter MCT9, is
mainly expressed in the kidney and adrenal glands. The
SLC16A9 SNP rs12356193 is associated with serum
uric acid levels (Kolz et al., 2009; van der Harst et al.,
2010; Köttgen et al., 2013). Elevated serum uric acid
levels are risk factors for gout and associated with
cardiovascular disease and diabetes. Another sequence
variant of the gene, rs2242206, was associated with
renal overload gout, but not with overall gout suscepti-
bility (Nakayama et al., 2013). MCT10, encoded by
SLC16A10, transports aromatic amino acids and is
highly expressed in skeletal muscle and in the heart.
One genome study addressing branched-chain amino
acid metabolism in nonalcoholic fatty liver disease
linked MCT10 to NAFLD with reduction in SLC16A10
gene expression in human disease development (Lake
et al., 2015). However, additional genetic studies in
larger populations and detailed knowledge on cellular
mechanisms are missing. Therefore, the potential of
MCT7, MCT9, and MCT10 in clinical therapies to treat
gout, fatty liver, and associated metabolic diseases
needs to be further investigated. Knockout mouse
strains would also be of great interest for these genes.
D. Solute Carrier 25 Family
Mitochondrial carriers are diverse in their substrate
specificity, and many are linked to human diseases
(Table 1). In addition to the discussed potential targets,
including the prominent uncoupling protein SLC25A7/
UCP1, SLC25A25/APC3 and SLC25A40/MCFP are
associated with diet-induced obesity in mice and hyper-
triglyceridemia in humans, respectively (Table 2).
1. Solute Carrier 25A25/ATP-Mg/Phosphate Carrier
Protein 3. SLC25A25 encodes the mitochondrial
APC3. It is ubiquitously expressed and, like APC1,
member of the subfamily of mitochondrial ATP-Mg/Pi
carrier proteins. The transporter has been characterized
in terms of metabolic function in Slc25a25 knockout mice.
The model exhibits resistance to diet-induced obesity as
well as reduced physical endurance (Anunciado-Koza
et al., 2011). Strikingly, the authors also found Slc25a25
to be upregulated in skeletal muscle and inguinal fat in
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cold-adaptedSlc25a7-deficientmice. Accordingly,Slc25a25
overexpression and deletion both result in reduced
metabolic efficiency. APC3 is proposed to maintain
ATP homeostasis by functioning as a Ca21-regulated
shuttle of ATP-Mg21 and phosphate, potentially result-
ing in impaired capacity for ATP synthesis necessary to
support Ca21 cycling in skeletal muscle. Loss of APC3
function may result in less efficient muscular activity,
shown by reduced exercise endurance on a treadmill,
and therefore, Slc25a25 knockout mice require more
caloric energy, which reduces fat stores and bodyweight
(Anunciado-Koza et al., 2011). Although human genetic
association data or mechanistic explanations linking
APC3 to metabolic disease are missing, the transporter
appears to be a promising candidate for further rodent
and human studies exploring its contribution to energy
metabolism and potential therapeutic applications.
2. Solute Carrier 25A40/Mitochondrial Carrier
Family Protein. SLC25A40 is ubiquitously expressed
at low levels and encodes theMCFP as one of the orphan
transporters of the SLC25 family with unknown sub-
strate specificity. The SLC25A40 single-nucleotide var-
iant rs762174003, probably resulting in reduced protein
function, is significantly associated with high circulat-
ing triglyceride levels, a common risk factor for T2D
and cardiovascular diseases (Rosenthal et al., 2013).
Another recent study addressed mechanisms of mito-
chondrial dysfunction after cardiopulmonary bypass in
patients with diabetes. SLC25A40, as well as PGC1a,
was significantly downregulated after cardiopulmonary
bypass in patients with diabetes, together with lower
levels of antioxidant marker and angiogenic and anti-
apoptotic factors (Mahmood et al., 2019). In this context,
MCFP may contribute to mitochondrial function. How-
ever, MCFP has not been functionally characterized or
investigated using mouse models; as such, its metabolic
role and links to hypertriglyceridemia and mitochon-
drial function in diabetes remain unclear.
E. Solute Carrier 30 Family
Within the SLC30 family, two members additional to
SLC30A8/ZnT8 (Table 1) are linked to metabolic abnor-
malities in rodents: SLC30A3/ZnT3 and SLC30A7/
ZnT7 (Table 2). However, their therapeutic potential
is unassigned because genome-wide association in
humans is missing. Other SLC30 genes are to date only
reported to be differentially expressed in obese subjects.
1. Solute Carrier 30A3/Zinc Transporter 3.
ZnT3, encoded by the SLC30A3 gene, is almost exclu-
sively localized in the brain and essential for zinc
transport into synaptic vesicles (Palmiter et al., 1996).
Slc30a3 knockdown in insulinoma cells lowered insu-
lin secretion, and knockout in a streptozotocin-induced
diabetes mouse model reduced glucose tolerance (Smidt
et al., 2009). In rats, altered Slc30a3 expression was
associated with fat pad weight (Keele et al., 2018).
SLC30A3 polymorphisms have not been linked to
human metabolic disease to date, rather to schizophre-
nia and Alzheimer’s disease (Rovelet-Lecrux et al.,
2012; Perez-Becerril et al., 2014). However, one human
study linked lowerSLC30A3 expression in adipocytes to
obesity (Smidt et al., 2007). Regarding existing cell-
based mouse and human data, although scarce, ZnT3
function is worth studying in more detail in the context
of metabolic disease.
2. Solute Carrier 30A7/Zinc Transporter 7.
ZnT7, encoded by the SLC30A7 gene, is mainly
expressed in the small intestine and mediates zinc
transport from the cytoplasm into the Golgi apparatus
(Kirschke and Huang, 2003). Slc30a7 knockout mice
showed a reduction in food intake, growth, and body
fat, and slightly elevated glucose levels after oral
glucose administration (Huang et al., 2007). Interest-
ingly, Slc30a7 is also expressed in the mouse pancreas,
and its overexpression in insulin-secreting b-cells ele-
vates insulin synthesis and secretion (Huang et al.,
2010). Diet-induced obese Slc30a7 knockout mice are
prone to metabolic changes, including glucose intoler-
ance and insulin resistance. The finding provides in vivo
evidence for a direct role of ZnT7 in the regulation of
glucose homeostasis (Huang et al., 2012). Insulin re-
sistance in this model was primarily associated with
increased intracellular fatty acid levels in skeletal
muscle, promoting intracellular lipid accumulation
and insulin resistance (Huang et al., 2018). In diabetic
rats, hyperglycemia-induced alteration of ZnT7 activity
causes zinc release from the sarco(endo)plasmic re-
ticulum and mediates endoplasmic reticulum stress in
the heart, which might contribute to cardiac dysfunc-
tion in diabetes (Tuncay et al., 2017, 2019). No func-
tional characterization of ZnT7 and link to diabetes in
humans has yet been described, but mouse data are
promising.
3. Other Solute Carrier 30 Transporters. Less evi-
dence for an association with metabolic disease is
present for other transporters of the family. Differential
gene expression in human visceral and subcutaneous
adipocytes between lean and obese subjects was shown
for SLC30A2 and SLC30A6 with a lower expression in
obese subjects, suggesting that obesity can influence the
adipocyte zinc-transporting system or vice versa (Smidt
et al., 2007). Another study, also addressing the mech-
anisms controlling zinc metabolism in obesity, ana-
lyzed expression of the SLC30 genes in leukocytes and
presented significantly lower SLC30A4, SLC30A5, and
SLC30A9 levels in leukocytes of obese women and the
inversely correlated expression of the genes with BMI
and body fat (Noh et al., 2014). However, no rodent and
human genetic data indicate the link to obesity-related
metabolic disorders, and the available human expres-
sion sets are poor, but there are existing hints that these
transporters might be deregulated in metabolic disease
and considered as therapeutic target. Within the SLC30
family and based onmouse data, SLC30A3 and SLC30A7
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seem to be the most interesting candidates besides
SLC30A8.
In conclusion, additional members of the SLC5,
SLC13, SLC16, SLC25, and SLC30 families were
identified to be associated with disease patterns in
humans and/or mice. Whether modulation of these
transporters could have any therapeutic potential
remains elusive. However, although links to human
metabolic disease areweak for these candidates, raising
the prevalence of diabetes and related metabolic dis-
eases requires novel medical approaches, and future
research on these SLC members shows promise.
VI. Conclusion and Outlook
In this review, we presented transporters of the SLC
superfamily that are linked to humanmetabolic disease
and may therefore be of interest for therapeutic in-
tervention. Remarkably, SGLT2 fulfills a special role
because it is, within the SLCs, the only already
validated drug target to treat metabolic disease. Cur-
rently, four SGLT2 inhibitors are FDA-approved:
canagliflozin, dapagliflozin, empagliflozin, and ertugli-
flozin. Importantly, SGLT2 inhibition was shown to
lower glucose levels, body weight, blood pressure, and
liver fat in clinical trials.
Two other SLC transporters have been linked to
metabolic disease in humans and/or mice and are
simultaneously targeted by drugs in clinical trials.
However, the ongoing clinical trials do not aim to treat
metabolic disease and/or target the SLC specifically.
The SLC16A1/MCT1 inhibitor AZD3965 is in clinical
testing as an anticancer agent. MCT1 is linked to
exercise-induced hyperinsulinemia in humans and obe-
sity, insulin resistance, and hepatic steatosis in mice,
and therefore reflects a candidate with high potential.
Furthermore, linifanib (ABT-869), an inhibitor of re-
ceptor tyrosine kinases, which is also in clinical testing
to treat different types of tumors, was most recently
identified as a potent inducer of SLC25A7/UCP1. The
essential role of UCP1 in body weight regulation and
diabetes is presented in various mouse and human
studies, and mitochondrial uncoupling is prominently
discussed to be effective against obesity. Therefore, the
AZD3965 and linifanib compounds are also promising
drugs for future trials in obesity, T2D, or related
metabolic diseases.
In contrast, none of the other candidates presented in
this review is described to be potently targeted by
compounds already in clinical testing. However, given
the large body of literature, the ideal novel drug targets
for the treatment of obesity, NAFLD, insulin resistance,
and T2D are SLC13A5/NaCT and SLC16A11/MCT11.
SLC13A5 gene expression was found to be associated
with hepatic steatosis in humans, and the knockout
mouse model was protected from obesity, fatty liver,
insulin resistance, and T2D. Specific NaCT inhibition
ameliorated these phenotypes, and NaCT is therefore
an attractive novel target to investigate in clinical
trials, although genome-wide association data are lack-
ing to date. Opposite to NaCT, which is missing in
GWAS, but well-characterized in terms of beneficial
metabolic effects using specific inhibitory compounds,
MCT11 is outstanding regarding the great number of
GWAS linking SLC16A11 polymorphisms to T2D in
various populations and moreover partially functional
characterization. However, no specific compound has
been described to date as activating MCT11 function,
the modulation of the transporter that most likely has
therapeutic benefit. Considering the short period of
research going on for NaCT andMCT11, compared with
the early discovery of renal inhibition of glucose trans-
port restoring blood glucose levels in humans mediated
by SGLT1 and SGLT2, or the link between brown
adipose tissue thermogenesis and obesity mediated by
UCP1, existing data are already promising, and con-
tinuing research will establish the novel candidates for
pharmacological intervention.
The transporter modulation needed to achieve bene-
ficial metabolic effects seems to be clear for NaCT and
MCT11, that is, they most likely need to be inhibited
and activated, respectively. Data on the involvement of
other candidates in metabolic disease are very strong,
for example, SLC30A8/ZnT8, but partially controversial
or at least diverse data do not permit a clear conclusion
as to whether an activating or inhibiting compound is
more likely to improve metabolic diseases. Neverthe-
less, as is the problem for most of the SLCs, structural
characterization is lacking and impedes the design of
small-molecule compounds. Therefore, research into
the three-dimensional structures of the transporters is
just as important as characterization on a functional
level to approach clinical trials in patients suffering
from diabetes and related metabolic disease.
Finally, multiple members of the SLC13, SLC16,
SLC25, and SLC30 families were linked to metabolic
disease in at least one human or mouse study. Impor-
tantly, we did not evaluate the druggability of our
proposed transporters, but the majority of SLCs is
expected to be generally druggable. Moreover, we
critically note that some of our proposed targets are
onlymarginally linked to metabolic diseases, defined by
disease patterns involved in obesity, fatty liver, insulin
resistance, b-cell loss, and T2D, or other abnormalities
in metabolic pathways that increase the risk of these
phenotypes. However, the main purpose of this review
was not only to present well-described SLC family
members with an obvious role in metabolic dysfunction
and multiple GWAS linking variants directly to obesity
or T2D, but also to raise interest in SLC transporters,
which are to date unsatisfactorily characterized and
underestimated in the scientific field, but potentially
also present novel targets for medical management of
diseases with increasing prevalence worldwide.
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